Post on 15-Nov-2021
DISCLOSURE APPENDIX AT THE BACK OF THIS REPORT CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, AND THE STATUS OF NON-US ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.
CREDIT SUISSE SECURITIES RESEARCH & ANALYTICS BEYOND INFORMATION®
Client-Driven Solutions, Insights, and Access
03 September 2014
Americas/United States
Equity Research
Biotechnology / Major Pharmaceuticals (Biotechnology (US)/Biotechnology &
Biopharmaceuticals (Europe)) / MARKET WEIGHT
ACTRIMS-ECTRIMS 2014 COMMENT
Continuing to Monitor The Revolution
Summary: The Joint ACTRIMS-ECTRIMS (“MSBoston”) Meeting 2014 starts
this time next week (Sep 10th-13
th) in Beantown. We will be attending. This
document provides a comprehensive planner for institutional investors,
organized by: (1) Key must-attend sessions (Exhibit 1–Exhibit 5); (2) Sessions
by company (Exhibit 11 –Exhibit 21); (3) Detailed sessions by day (Exhibit 22 –
Exhibit 34); (4) Education sessions (Exhibit 6 – Exhibit 10). From a data
perspective, the key focal points are (1) RCPT's RPC1063 (RADIANCE PII
data) on Saturday, (2) ABBV's/BIIB's Zinbryta (Daclizumab) (DECIDE PIII data)
on Thursday/Friday and (3) Synthon's Generic Copaxone (GATE PIII data) on
Friday. There will be incremental data on BIIB's and GSK’s remyelination
agents. From a market dynamics perspective, the conference also will
provide granularity on (1) the continued dominance of oral agents (particularly
BIIB’s Tecfidera); (2) Earlier and "treat aggressively/earlier and to goal"
management (vs. the old paradigm of “diagnose, treat, and see”); (3) Increasing
focus on MRI in diagnosis and treatment; (4) Individualized treatment
choice/emerging treatment guidelines (5) Potential of remyelination.
■ ABBV (TP$63, OP)/BIIB (TP$425, OP) – Zinbryta (Daclizumab):
Granularity of the DECIDE PIII data on MRI data (P051, Thu), safety and
tolerability (P094, Thu), as well as primary results (FC1.1, 8:15am to 9:15am
on Fri). Recall, headline data (45% ARR, 54% T2, 16% EDSS reductions)
were announced in June.
■ BIIB (TP$425, OP) – Tecfidera: Updated five-year follow-up data for
Tecfidera on MRI data (P059, Thu) and integrated clinical efficacy (P110,
Thu) of DEFINE CONFIRM, and ENDORSE (DEFINE/CONFIRM follow-up
trial). Recall four year data were presented in March at AAN. Anti-LINGO-1:
Potential biomarkers for BIIB033 activity in PI trials (P262, Thu); Baseline
patient characteristics for RENEW PII trial in acute optic neuritis (P731, Fri).
■ RCPT (TP$58, OP) – RPC1063: Granularity of RADIANCE PII data will be
presented in an oral session (LB1.1, Sat). Recall head line data was
disclosed in early June (6m, primary MRI GdE lesion 12-24w reduction of
86%). Focus at the meeting will be on ARR and CV/LFT safety granularity.
■ GSK (1475p, UP) – GSK239512: A poster will be presented on the design
of a PIIa trial evaluating effects on lesion remyelination in RMS patients
(P726, Thu). Ofatumumab (Partnered with Genmab, Not Covered): There
will be a poster on the follow-up data from the MIRROR PII trial (P048,
Thurs). MOR103 (Partnered with Morphosys, Not Covered): The PI data
(safety and pharmacokinetics) will be presented orally (FC2.4, Fri).
(Continued on next page…)
Research Analysts
Ravi Mehrotra PhD
212 325 3487
ravi.mehrotra@credit-suisse.com
Koon Ching PhD
212 325 6286
koon.ching@credit-suisse.com
European Pharma Team
44 207 888 0304
creditsuisse.pharmateam@credit-suisse.com
Vamil Divan, MD
212 538 5394
vamil.divan@credit-suisse.com
Anuj Shah
212 325 6931
anuj.shah@credit-suisse.com
Ronak H. Shah, Pharm.D., CFA
212 325 9799
ronak.shah@credit-suisse.com
Ari Jahja
212 325 0767
ariyanto.jahja@credit-suisse.com
Jason Kantor, PhD
415 249 7942
jason.kantor@credit-suisse.com
Jeremiah Shepard, PhD
415 249 7933
jeremiah.shepard@credit-suisse.com
03 September 2014
ACTRIMS-ECTRIMS 2014 2
(Continued from previous page…)
■ Novartis (SFr90, OP) – Gilenya: Presentations correlating brain volume change to
multiple sclerosis disease-activity freedom (FC1.5, Fri) and disability progression from
FREEDOMS and extension studies (FC2.3, Fri) will be given in an oral session. A
poster on using threshold rates of brain volume loss (P290, Thurs) will be presented
too. Siponimod: There will be posters on modeling of dose-PK-lymphocyte
relationships on immune reconstitution (P050, Thu) and concentration-efficacy
relationships for MRI lesion counts (P109, Thu).
■ Sanofi (TP€80, N) – Aubagio: There will be posters on subgroup MRI data from
TOPIC (P040, Thu), pooled subgroup efficacy/safety data from TEMSO and TOWER
(P046, Thu), and pooled safety data from the clinical development program (P097,
Thu). Lemtrada: Presentations on three-year disease free outcomes data from CARE-
MS trials (FC1.4, Fri) and three-year MRI outcomes from CARE-MS I (FC2.2, Fri) will
be given in an oral session. Posters will be given on subgroup data from CARE-MS I
(P090, Thu) and CARE-MS II (P043, P044, P103, Thu).
■ Synthon (Not Covered): Generic Glatriramer Acetate: Granularity of the GATE trial
will be presented (FC1.2, Fri).
■ TEVA (Not Covered) – Copaxone TIW: The safety/tolerability data from GLACIER will
be presented orally(FC3.2, Fri). There also will be posters on comparable clinical and
MRI efficacy data (vs. Copaxone QD) (P053, Thu), convenience (P080 Thu), and
safety/tolerability data (P100, P306, Thu).
■ XNPT (TP$7, OP): Data was seen previously. A poster on PI data (blood lymphocyte
responses and pharmacokinetics) will be provided (P958, Fri).
03 September 2014
ACTRIMS-ECTRIMS 2014 3
Key Sessions
Exhibit 1: Key Sessions – Wednesday, September 10, 2014 Wednesday - September 10, 2014
Time Location Type Drug Title Authors ID
08:00 - 09:30 312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General Choosing the right treatment for the right patient RJ Fox TC2.2
08:00 - 09:30 312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General When and how should MS treatment be switched
or escalated
BC Kieseier TC2.3
08:00 - 09:30 306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Optic nerve imaging: pathophysiological insights A Toosy TC7.1
08:00 - 09:30 306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Deep grey matter: current and new technologies MA Rocca TC7.2
10:00 - 11:30 312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Diagnostic approach to MS P Vermersch TC9.1
10:00 - 11:30 312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Red flags in MS: zebras or horses? S Galetta TC9.2
10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Lesions: can we go beyond counts and volumes? N De Stefano TC11.1
10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Brain atrophy: an outcome measure in clinical
studies
E Fisher TC11.2
10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Imaging biomarkers of normal-appearing brain D Pelletier TC11.3
10:00 - 11:30 304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Assessing drug efficacy: challenges in study
design
F Lublin TC13.1
10:00 - 11:30 304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Investigator initiated vs industry sponsored
studies, which and when - randomized trials in the
active treatment era
GR Cutter TC13.3
17:30 - 18:30 Auditorium Satellite Symposium Satellite
Symposium
Emerging Trends in MS Pathophysiology: The
Role of Mitochondria
Sanofi - - - - -
18:45 - 19:45 Auditorium Satellite Symposium Satellite
Symposium
Beyond Diagnosis: The Essential Role of MRI in
Clinical Management of Multiple Sclerosis
Biogen Idec - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 4
Exhibit 2: Key Sessions – Thursday, September 11, 2014 Thursday - September 11, 2014
Time Room Type Drug Title Authors ID
07:15 - 08:15 Auditorium Satellite Symposium Satellite
Symposium
Aligning Treatment Selection With Goals in
Multiple Sclerosis: How Can We Optimized
Established and Emerging Therapy in Clinical
Practice
Sanofi - - - - -
09:00 - 10:00 Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1
10:30 - 12:00 Auditorium Parallel Session 1: Cell-based
Therapies
General Assessing myelin repair in multiple sclerosis: Is
imaging useful? Usable? Are we there yet?
C Laule PS1.2
12:30 - 13:30 Auditorium Satellite Symposium Satellite
Symposium
Time for change: Advancing our understanding of
MS
Novartis - - - - -
15:30 - 17:00 Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple
sclerosis treated with teriflunomide: subgroup
analyses from the TOPIC phase 3 study
JS Wolinsky, P Truffinet, D Bauer, AE Miller, for
the Investigators of the TOPIC Study and the MRI-
AC in Houston, TX
P040
15:30 - 17:00 Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery
following relapses: data from the 2-year
ADVANCE relapsing-remitting multiple sclerosis
study
BC Kieseier, TF Scott, SD Newsome, SI Sheikh,
S Hung, X You, B Sperling
P042
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in patients
with relapsing-remitting MS who relapsed on prior
therapy: four-year follow-up of the CARE-MS II
study
H-P Hartung, DL Arnold, JA Cohen, AJ Coles, EJ
Fox, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS II Investigators
P043
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves quality of life in relapsing-
remitting multiple sclerosis patients who relapsed
on prior therapy: 3-year follow-up of CARE-MS II
T Moreau, DH Margolin, L Kasten, B Singer, on
behalf of the CARE-MS II Investigators
P044
15:30 - 17:00 Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups
defined by prior treatment: pooled analyses of the
phase 3 TEMSO and TOWER studies
MS Freedman, D Dukovic, M Benamor, P
Truffinet, L Kappos
P046
15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under
siponimod (BAF312) treatment to infer time to
immune reconstitution
C Sarr, M Savelieva, G Ette, C Petry, E
Legangneux, E Wallström
P050
15:30 - 17:00 Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,
double-blind trial of DAC HYP vs. IFNβ-1a in
RRMS patients
DL Arnold, L Kappos, E Havrdova, K Selmaj, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
P051
15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of
glatiramer acetate 40mg/mL TIW and 20mg/mL
QD: results of a systematic review and meta-
analysis
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P053
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in relapsing-remitting multiple sclerosis:
MRI outcomes from DEFINE, CONFIRM, and
ENDORSE
DL Arnold, RJ Fox, R Gold, E Havrdova, L
Kappos, T Yousry, D MacManus, R Zhang, M
Yang, NC Kurukulasuriya, V Viglietta
P059
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in
worsening relapsing-remitting multiple sclerosis
defined by baseline EDSS over 3
TL Vollmer, G Comi, L Kappos, X Montalban, G
Cutter, JR Steinerman, N Sasson, T Gorfine, V
Knappertz,
P062
15:30 - 17:00 Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures
and freedom from measured disease activity: 2-
year results from the phase 3 ADVANCE study
DL Arnold, PA Calabresi, BC Kieseier, SI Sheikh,
A Deykin, S Liu, X You, B Sperling, S Hung
P067
15:30 - 17:00 Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and
disease factors on risk of physical deterioration in
patients with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P074
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 5
Exhibit 3: Key Sessions – Thursday, September 11, 2014 Thursday - September 11, 2014
Time Room Type Drug Title Authors ID
15:30 - 17:00 Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in
patients with relapsing-remitting multiple sclerosis:
2-year data from the ADVANCE study
BC Kieseier, PA Calabresi, Y Cui, Y Zhu, S Hung,
A Deykin, A Seddighzadeh
P085
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in treatment-
naive patients with relapsing-remitting MS: four-
year follow-up of the CARE-MS I study
AJ Coles, DL Arnold, JA Cohen, EJ Fox, H-P
Hartung, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS I Investigators
P090
15:30 - 17:00 Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP
treatment in relapsing-remitting multiple sclerosis:
results of the DECIDE study
K Selmaj, L Kappos, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, K Riester, M Sweetser,
J Elkins
P094
15:30 - 17:00 Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide
clinical development program
TP Leist, MS Freedman, L Kappos, TP Olsson,
AE Miller, JS Wolinsky, PW O'Connor, M
Benamor, P Truffinet, D Dukovic, G Comi0
P097
15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate
40mg/mL TIW and 20mg/mL QD dosing regimen
effects on relapse rate: results of a predictive
statistical model
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P100
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes in
relapsing-remitting multiple sclerosis patients who
relapsed on prior therapy: three-year follow-up of
E Fisher, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, DL Arnold, on
behalf of the CARE-MS II Investigators
P103
15:30 - 17:00 Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP
pharmacokinetics from three phase 1 studies
AA Othman, JQ Tran, MT Tang, S Dutta P106
15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for
MRI lesion counts under siponimod treatment and
its dependence on the effect on lymphocyte
reduction
M Savelieva, E Wallström P109
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in RRMS: integrated clinical efficacy
data from the DEFINE, CONFIRM, and
ENDORSE studies
R Gold, JT Phillips, A Bar-Or, M Hutchinson, L
Kappos, R Zhang, M Yang, NC Kurukulasuriya, V
Viglietta, RJ Fox
P110
15:30 - 17:00 Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1
clinical studies
S Ray, J Tran, S Ciotti, Q Duong, R Huang, L
Yang, D Cadavid
P262
15:30 - 17:00 Hall C Poster Session 1 Gilenya vs.
Tecfidera
Persistence with fingolimod versus dimethyl
fumarate in patients with multiple sclerosis:
retrospective analysis of US open source
pharmacy data
N Bergvall, R Lahoz, T Nazareth, JR Korn P289
15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site
reactions with glatiramer acetate 40mg/mL three
times weekly dosing
JS Wolinsky, Y Sidi, JR Steinerman, V Knappertz,
S Kolodny, The GLACIER Study Group
P306
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release
dimethyl fumarate in a multicenter, open-label
study of patients with relapsing multiple sclerosis
EJ Fox, A Vasquez, W Grainger, TS Ma, C von
Hehn, J Walsh, J Li, J Zambrano
P309
15:30 - 17:00 Hall C Poster Session 1 General The changing face of MS: does ARR vary by
epoch?
BC Healy, T Chitnis, F Dangond, HL Weiner P342
18:00 - 19:00 Auditorium Satellite Symposium Satellite
Symposium
Evolving Insights Into MS Pathology: Can We
Ever Stop Disease Worsening?
Teva - - - - -
19:15 - 20:15 Small Ballroom Satellite Symposium Satellite
Symposium
Innovation and Optimization: Engaging Today's
Patients
Merck KGaA - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 6
Exhibit 4: Key Sessions – Friday, September 12, 2014 Friday - September 12, 2014
Time Room Type Drug Title Authors ID
08:15 - 09:15 Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-
blind, double-dummy, active-controlled trial of
daclizumab HYP vs. Interferon β-1a in RRMS
patients
L Kappos, K Selmaj, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
FC1.1
08:15 - 09:15 Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to
copaxone on efficacy and safety: results of the
randomized double-blind GATE trial in multiple
sclerosis
JA Cohen, A Belova, K Selmaj, C Wolf, JJL
Oberyé, ERW van den Tweel, NP Koper, G
Voortman, F Barkhof, on behalf of the GATE
Study Group
FC1.2
08:15 - 09:15 Auditorium Free Communication 1 Alemtuzumab Disease-free outcomes with alemtuzumab: 3-year
follow-up of the CARE-MS studies
E Havrdova, DL Arnold, J Palmer, DH Margolin,
on behalf of CARE-MS I and CARE-MS II Study
Investigators
FC1.4
08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 Alemtuzumab Alemtuzumab improves MRI outcomes in
treatment-naive active relapsing-remitting multiple
sclerosis patients: three-year follow-up from
CARE-MS I
DL Arnold, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, E Fisher, on
behalf of CARE-MS I Investigators
FC2.2
08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 Gilenya Brain volume change by quartile and disability
progression in multiple sclerosis: a 4-year analysis
of the phase 3 FREEDOMS trial and its extension
D Jeffery, E Verdun, D Piani Meier, S Ritter, P
Chin, E-W Radue, W Camu
FC2.3
08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 MOR103 Safety and pharmacokinetics of MOR103, a
human antibody to granulocyte-macrophage
colony-stimulating factor, in patients with multiple
sclerosis
CS Constantinescu, A Asher, W Fryze, W
Kozubski, F Wagner, JJ Aram, R Tanasescu, RP
Korolkiewicz, S Steidl, T Sprenger, WE Radue
FC2.4
08:15 - 09:15 Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in
relapsing-remitting multiple sclerosis: 2-year data
from the phase 3 ADVANCE study
PA Calabresi, BC Kieseier, DL Arnold, L Balcer, A
Boyko, J Pelletier, S Liu, Y Zhu, SI Sheikh, A
Seddighzadeh, A Deykin, S Hung
FC2.5
08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized
safety/tolerability study of glatiramer acetate
40mg/mL three times weekly versus 20mg/mL
daily in RRMS
JS Wolinsky, DW Dietrich, TE Borresen, BF
Gilder, JR Steinerman, Y Sidi, A Vainstein, S
Kolodny, V Knappertz, GLACIER Study Group
FC3.2
09:45 - 11:15 Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers General Biomarkers of treatment response to MS disease
therapies
S Dhib-Jalbut PS7.2
09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing
neuroprotection
General Update on completed and ongoing
neuroprotection and repair trials
J Chataway PS8.2
12:00 - 13:00 Auditorium Satellite Symposium Satellite
Symposium
Evolving Strategies to Improve Patient-Clinician
Communication and Treatment Adherence in
Multiple Sclerosis
Teva - - - - -
14:45 - 16:15 Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion
remyelination in a relapsing remitting MS
population: design of a phase 2a imaging study
C Schwartzbach, R Grove, P Thompson, O Graff,
MA Peykamian, K Harding, J Hilpert, R Brown, D
Arnold
P726
14:45 - 16:15 Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal
antibody, BIIB033, in subjects with acute optic
neuritis: baseline data
D Cadavid, F Ziemssen, H Butzkueven, LJ Balcer,
SL Galetta, A Rahilly, T Dong-Si, L Xu, T
Ziemssen, RENEW Study Group
P731
14:45 - 16:15 Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory
function (MSWS-12) and objective disability
measurements in SPMS: analysis of ASCEND
baseline data
D Mikol, MS Freedman, MD Goldman, H-P
Hartung, E Havrdova, D Jeffery, R Kapoor, A
Miller, F Sellebjerg, D Cadavid, Y Chen
P777
14:45 - 16:15 Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and
injection site reactions on quality of life in patients
with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P799
14:45 - 16:15 Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood
lymphocyte responses in healthy subjects dosed
with XP23829, a novel fumaric acid ester for
multiple sclerosis
L Steinman, RJ Fox, D Lissin, L Clark, K Cundy P958
17:15 - 18:15 Auditorium Satellite Symposium Satellite
Symposium
Treatment Decisions at the Interactions of Trials
and Practice
Biogen idec - - - - -
18:30 - 19:30 Small Ballroom Satellite Symposium Satellite
Symposium
Treating to target and beyond: Is improvement in
functioning a realistic treatment goal in multiple
sclerosis?
AbbVie - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 7
Exhibit 5: Key Sessions – Saturday, September 13, 2014 Saturday - September 13, 2014
Time Room Type Title Authors ID
07:15 - 08:15 Small Ballroom
(302-304-306)
Industry Support Satellite Symposia Satellite
Symposium
Shifting the Paradigm in Multiple Sclerosis
Treatment by Targeting New Pathways
Roche - - - - -
08:30 - 10:00 Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a
randomized, double-blind, placebo-controlled trial
of oral RPC1063 in relapsing multiple sclerosis
J Cohen, DL Arnold, G Comi, A Bar-Or, S
Gujrathi, JP Hartung, A Olson, M Cravets, PA
Frohna, K Selmaj
LB1.1
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 8
Sessions by Company/Type
Exhibit 6: General/Satellite Symposium Sessions General
Key? Time Location Type Drug Title Authors ID
08:00 - 09:30
Wed - 9/10
304 Teaching Course 1: Current
controversy in management:
Interactive case discussion
General Current controversy in management: interactive
case discussion
AE Miller TC1.1
08:00 - 09:30
Wed - 9/10
312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General Treating CIS and early RRMS: pros and cons A Goodyear TC2.1
●08:00 - 09:30
Wed - 9/10
312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General Choosing the right treatment for the right patient RJ Fox TC2.2
●08:00 - 09:30
Wed - 9/10
312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General When and how should MS treatment be switched
or escalated
BC Kieseier TC2.3
08:00 - 09:30
Wed - 9/10
310 Teaching Course 3: Symptom
management
General Symptom management - focus on gait impairment A Goodman TC3.1
08:00 - 09:30
Wed - 9/10
310 Teaching Course 3: Symptom
management
General Effective management of spasticity AJ Thompson TC3.2
08:00 - 09:30
Wed - 9/10
310 Teaching Course 3: Symptom
management
General Exercise therapy as symptomatic treatment U Dalgas TC3.3
08:00 - 09:30
Wed - 9/10
313 Teaching Course 5: Clinically
isolated syndromes (CIS)
General Radiologically isolated syndrome: pre-
symptomatic MS?
DT Okuda TC5.1
08:00 - 09:30
Wed - 9/10
313 Teaching Course 5: Clinically
isolated syndromes (CIS)
General How can we treat and manage CIS patients? M Tintore TC5.3
●08:00 - 09:30
Wed - 9/10
306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Optic nerve imaging: pathophysiological insights A Toosy TC7.1
●08:00 - 09:30
Wed - 9/10
306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Deep grey matter: current and new technologies MA Rocca TC7.2
10:00 - 11:30
Wed - 9/10
310 Teaching Course 8: Update in
pediatric MS
General Diagnosis of MS and acute demyelinating
disorders in children
C Hemingway TC8.1
10:00 - 11:30
Wed - 9/10
310 Teaching Course 8: Update in
pediatric MS
General Emerging therapies and clinical trials in pediatric
MS
T Chitnis TC8.2
10:00 - 11:30
Wed - 9/10
310 Teaching Course 8: Update in
pediatric MS
General MRI: role in assessment of MS disease activity
and disease impact in patients with MS onset
during childhood
BL Banwell TC8.3
●10:00 - 11:30
Wed - 9/10
312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Diagnostic approach to MS P Vermersch TC9.1
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 9
Exhibit 7: General/Satellite Symposium Sessions General
Key? Time Location Type Drug Title Authors ID
●10:00 - 11:30
Wed - 9/10
312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Red flags in MS: zebras or horses? S Galetta TC9.2
10:00 - 11:30
Wed - 9/10
312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General MS differential diagnoses E Waubant TC9.3
10:00 - 11:30
Wed - 9/10
302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Inadequate activation of T cells in MS: possible
mechanisms involved
RS LIBLAU TC10.1
10:00 - 11:30
Wed - 9/10
302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Contribution of B cell: T cell interactions to CNS
inflammation in MS
A Bar-Or TC10.2
10:00 - 11:30
Wed - 9/10
302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Immune cell trafficking to the CNS, mechanisms
and therapeutic implications
MH Han TC10.3
●10:00 - 11:30
Wed - 9/10
311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Lesions: can we go beyond counts and volumes? N De Stefano TC11.1
●10:00 - 11:30
Wed - 9/10
311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Brain atrophy: an outcome measure in clinical
studies
E Fisher TC11.2
●10:00 - 11:30
Wed - 9/10
311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Imaging biomarkers of normal-appearing brain D Pelletier TC11.3
10:00 - 11:30
Wed - 9/10
313 Teaching Course 12: Neuro-
opthalmology update
General Visual manifestations of CNS demyelinating
disorders
FE Costello TC12.1
10:00 - 11:30
Wed - 9/10
313 Teaching Course 12: Neuro-
opthalmology update
General The role of visual outcomes in MS clinical trials LJ Balcer TC12.3
●10:00 - 11:30
Wed - 9/10
304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Assessing drug efficacy: challenges in study
design
F Lublin TC13.1
10:00 - 11:30
Wed - 9/10
304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Assessing treatment efficacy in MS: observational
studies vs clinical trials
MP Sormani TC13.2
●10:00 - 11:30
Wed - 9/10
304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Investigator initiated vs industry sponsored
studies, which and when - randomized trials in the
active treatment era
GR Cutter TC13.3
10:00 - 11:30
Wed - 9/10
306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General The manifestations of cognitive and psychiatric
disorders in MS and assessment strategies
R Benedict TC14.1
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 10
Exhibit 8: General/Satellite Symposium Sessions General
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Wed - 9/10
306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General Treatment of disorders of mood and affect in MS
patients
A Feinstein TC14.2
10:00 - 11:30
Wed - 9/10
306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General Treatment of cognitive dysfunction in MS patients MP Amato TC14.3
●17:30 - 18:30
Wed - 9/10
Auditorium Satellite Symposium Satellite
Symposium
Emerging Trends in MS Pathophysiology: The
Role of Mitochondria
Sanofi - - - - -
●18:45 - 19:45
Wed - 9/10
Auditorium Satellite Symposium Satellite
Symposium
Beyond Diagnosis: The Essential Role of MRI in
Clinical Management of Multiple Sclerosis
Biogen Idec - - - - -
●
07:15 - 08:15
Thus - 9/11
Auditorium Satellite Symposium Satellite
Symposium
Aligning Treatment Selection With Goals in
Multiple Sclerosis: How Can We Optimized
Established and Emerging Therapy in Clinical
Practice
Sanofi - - - - -
●10:00 - 11:30
Thu - 9/11
Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1
●10:00 - 11:30
Thu - 9/11
Auditorium Parallel Session 1: Cell-based
Therapies
General Assessing myelin repair in multiple sclerosis: Is
imaging useful? Usable? Are we there yet?
C Laule PS1.2
10:00 - 11:30
Thu - 9/11
Small Ballroom
(302-304-306)
Parallel Session 4: EAE and other
animal models
General What can EAE teach us about MS? JM Goverman, MC Johnson, ER Pierson, SB
Simmons
PS4.1
10:00 - 11:30
Thu - 9/11
Auditorium Parallel Session 6: Risk
management with MS Therapy
General PML with novel immunotherapies: Is there light at
the end of the tunnel?
R Gold PS6.1
●12:30 - 13:30 Auditorium Satellite Symposium Satellite
Symposium
Time for change: Advancing our understanding of
MS
Novartis - - - - -
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 General Time to relapse among propensity score matched
patients receiving disease modifying therapy for
multiple sclerosis
BH Johnson, MM Bonafede, C Watson P304
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 General Real-world titration of disease modifying therapies
in the treatment of multiple sclerosis: findings
from a survey of neurologists
T Nazareth, J Marvel, S Sikirica, J Xie, W
Reichmann, C Zhao, R Sasane
P307
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 General The changing face of MS: does ARR vary by
epoch?
BC Healy, T Chitnis, F Dangond, HL Weiner P342
15:30 - 17:00
Thu - 9/11
Auditorium Hot Topic 2: New routes of drug
development
General Repurposing drugs for disease modification in
multiple sclerosis
K Schmierer HT2.1
15:30 - 17:00
Thu - 9/11
Auditorium Hot Topic 2: New routes of drug
development
General A perspective on generic medications to treat MS JA Cohen HT2.2
15:30 - 17:00
Thu - 9/11
Auditorium Hot Topic 2: New routes of drug
development
General From genetic findings to drug discovery: taking
the first step
NA Patsopoulos, JM Replogle, HT2.3
15:30 - 17:00
Thu - 9/11
Small Ballroom
(302-304-306)
Hot Topic 3: Symptomatic and
rehabilitation strategies
General Cognitive impairment MP Amato HT3.1
●18:00 - 19:00
Thus - 9/11
Auditorium Satellite Symposium Satellite
Symposium
Evolving Insights Into MS Pathology: Can We
Ever Stop Disease Worsening?
Teva - - - - -
●19:15 - 20:15
Thus - 9/11
Small Ballroom Satellite Symposium Satellite
Symposium
Innovation and Optimization: Engaging Today's
Patients
Merck KGaA - - - - -
●17:00 - 17:45
Fri - 9/12
Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers General Biomarkers of treatment response to MS disease
therapies
S Dhib-Jalbut PS7.2
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 11
Exhibit 9: General/Satellite Symposium Sessions General
Key? Time Room Type Drug Title Authors ID
17:00 - 17:45
Fri - 9/12
Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers General Immunological biomarkers that identify MS
patients with high probability of being free of
disease activity if treated with IFN-beta
JC Alvarez-Cermeño, R Alenda, L Costa-
Frossard, R Alvarez-Lafuente, C Picon, M Espiño,
E Roldan, R Arroyo, E Rodriguez-Martin, LM Villar
PS7.3
17:00 - 17:45
Fri - 9/12
Grand Ballroom Parallel Session 8: Assessing
neuroprotection
General Pathways to neurodegeneration: insights from
imaging in MS and other neurodegenerative
disorders
M Inglese PS8.1
●08:15 - 09:15
Fri - 9/12
Grand Ballroom Parallel Session 8: Assessing
neuroprotection
General Update on completed and ongoing
neuroprotection and repair trials
J Chataway PS8.2
08:15 - 09:15
Fri - 9/12
Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Differentiation and quantification of inflammation,
demyelination, and axon injury in human multiple
sclerosis using diffusion basis spectrum imaging
Y Wang, P Sun, Q Wang, C-W Chiang, RE
Schmidt, RT Naismith, AH Cross, S-K Song
PS8.6
08:15 - 09:15
Fri - 9/12
Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Is no evidence of disease activity a realistic
treatment target?
H-P Hartung PS9.1
08:15 - 09:15
Fri - 9/12
Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Treatment algorithms in patients with ongoing
disease activity
X Montalban PS9.2
08:15 - 09:15
Fri - 9/12
Grand Ballroom Parallel Session 11: Gray matter
pathology and mechanisms of
progression
General Demyelinating lesions in multiple sclerosis:
experimental evidence indicating why, how and
where they may form
RA Desai, AL Davies, M Kasti, F Laulund, KJ
Smith
PS10.3
08:15 - 09:15
Fri - 9/12
Auditorium Parallel Session 12: Study design
and endpoints
General Is primary progressive MS a distinct disease? S Vukusic PS11.2
08:15 - 09:15
Fri - 9/12
Auditorium Parallel Session 12: Study design
and endpoints
General Pragmatic clinical trials and observational studies M Trojano PS12.2
08:15 - 09:15
Fri - 9/12
Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Defining brain volume cut-offs to predict disability
progression in MS: an analysis of a large cohort of
relapsing-remitting MS patients
MP Sormani, L Kappos, EW Radue, J Cohen, F
Barkhof, T Sprenger, D Piani Meier, D Häring, D
Tomic, N De Stefano
PS12.3
08:15 - 09:15
Fri - 9/12
Hall C Poster Session 2 General Histamine H3 receptor negatively regulates
oligodendrocyte differentiation and myelination
RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY
Zhao, AA Liu, JP Rubio, D Krull, J Lu, M Song, P
Thompson, S Wang, JC Richardson
P621
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 General Optic neuritis associated with multiple sclerosis:
VEPs sensitive in acute phase, OCT useful in
chronic phase
G Di Maggio, RI Santangelo, S Guerrieri, L
Ferrari, S Medaglini, M Rodegher, B Colombo, L
Moiola, U Del Carro, V Martinelli, G Comi, L
Leocani
P676
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 General Visual evoked potentials and optic coherence
tomography in monitoring involvement of visual
pathways in multiple sclerosis
L Leocani, S Guerrieri, G Di Maggio, R
Santangelo, L Ferrari, S Medaglini, M Rodegher,
B Colombo, L Moiola, U Del Carro, V Martinelli, G
Comi
P704
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 General Small molecule inducers of oligodendrocyte
differentiation
B Bai, R Avila, M Torres-Castillo, S Lunn, S
Medicetty, B Trapp
P721
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 12
Exhibit 10: General/Satellite Symposium Sessions General
Key? Time Room Type Drug Title Authors ID
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 General A high throughput flow cytometry based approach
to assess the differentiation of oligodendrocyte
precursor cells into mature oligodendrocytes
C Hollins, H Sandig, C Glover, C Jones, M
Sleeman
P728
●12:00 - 13:00
Fri - 9/12
Auditorium Satellite Symposium Satellite
Symposium
Evolving Strategies to Improve Patient-Clinician
Communication and Treatment Adherence in
Multiple Sclerosis
Teva - - - - -
13:15 - 14:45
Fri - 9/12
Hall C Poster Session 2 General Clinical and molecular markers that predict
severity of relapsing-remitting MS (RRMS)
disease outcomes
J Goyal, J Bienkowska, R Hosur, M Yang, S
Feng, V Viglietta, D Mikol
P761
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 General Identifying an important change threshold for the
Multiple Sclerosis Walking Scale-12 (MSWS-12)
L Mehta, M McNeill, J Hobart, K Wyrwich, JL
Poon, P Auguste, ZJ Zhong, J Elkins
P783
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 General Psychometric testing of the early mobility
impairment questionnaire for multiple sclerosis
T Ziemssen, A Mathias, C Coon, S Agarwal, R
Shah, G Phillips
P784
14:45 - 16:15
Fri - 9/12
Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Epigenome-wide studies: what can we learn from
them?
P Casaccia HT4.1
14:45 - 16:15
Fri - 9/12
Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Remyelination in the adult central nervous
system: mechanisms and perspectives
C Lubetzki HT4.2
14:45 - 16:15
Fri - 9/12
Grand Ballroom Hot Topic 5: Inflammation and
neurodegeneration
General Fluorosamine that targets scar components is a
novel therapeutic that promotes myelin
regeneration and reduces inflammation in
demyelination models
M Keough, J Rogers, P Zhang, S Jensen, E
Stephenson, J Plemel, M Hurlbert, C-C Ling, VW
Yong
HT4.3
14:45 - 16:15
Fri - 9/12
Auditorium Hot Topic 6: Society and MS General Neuro-axonal damage in MS may be mediated by
interaction of innate immunity and anti-axonal
antibodies
JD Black, MS Freedman HT5.3
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 General Patients as partners in clinical research - Does
the Internet harm or help?
P Wicks HT6.2
●17:15 - 18:15
Fri - 9/12
Auditorium Satellite Symposium Satellite
Symposium
Treatment Decisions at the Interactions of Trials
and Practice
Biogen idec - - - - -
●18:30 - 19:30
Fri - 9/12
Small Ballroom Satellite Symposium Satellite
Symposium
Treating to target and beyond: Is improvement in
functioning a realistic treatment goal in multiple
sclerosis?
AbbVie - - - - -
●07:15 - 08:15
Sat - 9/13
Small Ballroom
(302-304-306)
Industry Support Satellite Symposia Satellite
Symposium
Shifting the Paradigm in Multiple Sclerosis
Treatment by Targeting New Pathways
Roche - - - - -
14:45 - 16:15
Sat - 9/13
Auditorium Late Breaking News General The Genomic map of multiple sclerosis: over 45
novel susceptibility variants and translation of
genetics to biology
P De Jager, International MS Genetics
Consortium
LB1.4
14:45 - 16:15
Sat - 9/13
Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Clinical Research Highlights Speaker: Ellen Mowry PL2.2
14:45 - 16:15
Sat - 9/13
Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Basic Research Highlights Speaker: Finn Sellebjerg PL2.3
16:15 - 17:00
Sat - 9/13
Outside Hall C Late Breaking News Posters General Oligodendroglial cells and signs of remyelination
are present in a subset of early active and inactive
MS lesions despite pronounced axonal damage
E Bahn, C Theodossiou-Wegner, W Brück LBP9
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 13
Exhibit 11: Acorda Acorda
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Ampyra Treatment patterns and budget impact of
dalfampridine in multiple sclerosis: a retrospective
claims database analysis
S Palli, M Sidovar, M Grabner, A Guo P010
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Ampyra Evaluation of patient health status in the PR-
fampridine ENABLE study using SF-36-derived
utility scores
A Lee, P Wang, M Yeh P785
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Ampyra Walking ability and balance in patients with
multiple sclerosis treated with prolonged-release
fampridine: randomized, double-blind MOBILE
study
R Hupperts, J Lycke, C Short, C Gasperini, M
McNeill, R Medori, L Mehta, J Elkins
P922
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Ampyra Safety, quality of life, and walking ability with PR-
fampridine treatment in clinical practice in France:
interim results of the LIBERATE study
J-P Neau, G Castelnovo, T Soisson, A
Kwiatkowski, M McNeill, M Yeh
P924
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
Exhibit 12: Bayer Bayer
Key? Time Room Type Drug Title Authors ID
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Betaseron Interferon beta-1b in treatment-naïve paediatric
patients with relapsing-remitting MS: baseline
data from the BETAPAEDIC study
J Gärtner, W Brück, A Weddige, K Reinhardt, JP
Bugge, The BETAPAEDIC Study Group
P089
14:45 - 16:15
Sat - 9/13
Outside Hall C Late Breaking News Posters Betaseron Clinical outcomes in patients with CIS treated with
interferon beta-1b: 11-year follow-up of BENEFIT
L Kappos, G Edan, MS Freedman, X Montalbán,
DH Miller, H-P Hartung, B Hemmer, EJ Fox, F
Barkhof, S Schippling0, A Schulze, D Pleimes, C
Pohl, R Sandbrink, G Suarez, E-M Wicklein, on
behalf of the BENEFIT Study Group
LBP17
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 14
Exhibit 13: Biogen Idec Biogen Idec
Key? Time Room Type Drug Title Authors ID
●10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery
following relapses: data from the 2-year
ADVANCE relapsing-remitting multiple sclerosis
study
BC Kieseier, TF Scott, SD Newsome, SI Sheikh,
S Hung, X You, B Sperling
P042
●
10:30 - 12:00
Thu - 9/11
Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,
double-blind trial of DAC HYP vs. IFNβ-1a in
RRMS patients
DL Arnold, L Kappos, E Havrdova, K Selmaj, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
P051
10:30 - 12:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Effect of bismuth subsalicylate on gastrointestinal
events associated with delayed-release dimethyl
fumarate: a double-blind, placebo-controlled study
C Tornatore, J Li, TS Ma, C von Hehn, J Walsh, J
Zambrano
P052
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Delayed-release dimethyl fumarate and disability
assessed by the multiple sclerosis functional
composite: integrated analysis of DEFINE and
CONFIRM
G Giovannoni, R Gold, L Kappos, DL Arnold, A
Bar-Or, NC Kurukulasuriya, M Yang, SP Sarda
P057
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in relapsing-remitting multiple sclerosis:
MRI outcomes from DEFINE, CONFIRM, and
ENDORSE
DL Arnold, RJ Fox, R Gold, E Havrdova, L
Kappos, T Yousry, D MacManus, R Zhang, M
Yang, NC Kurukulasuriya, V Viglietta
P059
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Long-term efficacy of delayed-release dimethyl
fumarate in newly diagnosed patients with RRMS:
an integrated analysis of DEFINE, CONFIRM, and
ENDORSE
R Gold, G Giovannoni, JT Phillips, RJ Fox, A
Zhang, NC Kurukulasuriya
P064
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate for
RRMS in prior interferon users in the DEFINE and
CONFIRM studies
Ó Fernández, G Giovannoni, RJ Fox, R Gold, JT
Phillips, M Okwuokenye, A Zhang, NC
Kurukulasuriya
P065
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Long-term follow-up of the safety of delayed-
release dimethyl fumarate in RRMS: interim
results from the ENDORSE extension study
C Pozzilli, JT Phillips, RJ Fox, K Selmaj, R Zhang,
M Novas, MT Sweetser, R Gold
P066
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures
and freedom from measured disease activity: 2-
year results from the phase 3 ADVANCE study
DL Arnold, PA Calabresi, BC Kieseier, SI Sheikh,
A Deykin, S Liu, X You, B Sperling, S Hung
P067
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tysabri Quantifying the effect of natalizumab on the total
disability burden of MS patients in AFFIRM using
an exploratory area under the curve analysis
RA Rudick, S Shang, Q Dong, D Paes, D Mikol, S
Belachew
P073
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and
disease factors on risk of physical deterioration in
patients with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P074
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Lymphocyte count reductions with delayed-
release dimethyl fumarate: integrated analysis of
the phase 2, phase 3, and extension studies
RJ Fox, A Chan, R Gold, JT Phillips, K Selmaj, R
Zhang, H Yuan, M Novas, V Viglietta, NC
Kurukulasuriya
P077
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in
patients with relapsing-remitting multiple sclerosis:
2-year data from the ADVANCE study
BC Kieseier, PA Calabresi, Y Cui, Y Zhu, S Hung,
A Deykin, A Seddighzadeh
P085
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP
treatment in relapsing-remitting multiple sclerosis:
results of the DECIDE study
K Selmaj, L Kappos, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, K Riester, M Sweetser,
J Elkins
P094
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Differential recovery from relapse between
treatment groups in the CONFIRM study of
delayed-release dimethyl fumarate
A Chan, JT Phillips, RJ Fox, A Zhang, M
Okwuokenye, NC Kurukulasuriya
P096
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 15
Exhibit 14: Biogen Idec Biogen Idec
Key? Time Room Type Drug Title Authors ID
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP
pharmacokinetics from three phase 1 studies
AA Othman, JQ Tran, MT Tang, S Dutta P106
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate in
multiple sclerosis patients with moderate
disability: an integrated analysis of the phase 3
studies
M Hutchinson, A Zhang, M Yang, M Okwuokenye,
NC Kurukulasuriya, RJ Fox, R Gold
P108
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in RRMS: integrated clinical efficacy
data from the DEFINE, CONFIRM, and
ENDORSE studies
R Gold, JT Phillips, A Bar-Or, M Hutchinson, L
Kappos, R Zhang, M Yang, NC Kurukulasuriya, V
Viglietta, RJ Fox
P110
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tysabri Natalizumab decreases progression of disability in
RRMS patients as measured by the composite
EDSS-Plus in AFFIRM
Q Dong, RA Rudick, D Paes, D Mikol, S Belachew P113
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1
clinical studies
S Ray, J Tran, S Ciotti, Q Duong, R Huang, L
Yang, D Cadavid
P262
● Thu - 9/11 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release
dimethyl fumarate in a multicenter, open-label
study of patients with relapsing multiple sclerosis
EJ Fox, A Vasquez, W Grainger, TS Ma, C von
Hehn, J Walsh, J Li, J Zambrano
P309
●
15:30 - 17:00
Fri - 9/12
Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-
blind, double-dummy, active-controlled trial of
daclizumab HYP vs. Interferon β-1a in RRMS
patients
L Kappos, K Selmaj, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
FC1.1
●15:30 - 17:00
Fri - 9/12
Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in
relapsing-remitting multiple sclerosis: 2-year data
from the phase 3 ADVANCE study
PA Calabresi, BC Kieseier, DL Arnold, L Balcer, A
Boyko, J Pelletier, S Liu, Y Zhu, SI Sheikh, A
Seddighzadeh, A Deykin, S Hung
FC2.5
17:00 - 17:45
Fri - 9/12
Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers Tecfidera Long-term follow-up of the effect of delayed-
release dimethyl fumarate on no evident disease
activity in patients with multiple sclerosis
G Giovannoni, R Gold, RJ Fox, L Kappos, T
Phillips, A Zhang, NC Kurukulasuriya, E Havrdova
FC3.5
●13:15 - 14:45
Fri - 9/12
Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal
antibody, BIIB033, in subjects with acute optic
neuritis: baseline data
D Cadavid, F Ziemssen, H Butzkueven, LJ Balcer,
SL Galetta, A Rahilly, T Dong-Si, L Xu, T
Ziemssen, RENEW Study Group
P731
●14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory
function (MSWS-12) and objective disability
measurements in SPMS: analysis of ASCEND
baseline data
D Mikol, MS Freedman, MD Goldman, H-P
Hartung, E Havrdova, D Jeffery, R Kapoor, A
Miller, F Sellebjerg, D Cadavid, Y Chen
P777
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Tecfidera An interim analysis of quality of life in patients with
relapsing-remitting multiple sclerosis treated with
delayed-release dimethyl fumarate
M Kita, RJ Fox, R Gold, G Giovannoni, T Phillips,
SP Sarda, M Okwuokenye, J Kong, R Zhang, NC
Kurukulasuriya, L Kappos
P790
●14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and
injection site reactions on quality of life in patients
with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P799
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Tecfidera Delayed-release dimethyl fumarate and
pregnancy: preclinical studies and pregnancy
outcomes from clinical trials and postmarketing
experience
R Gold, JT Phillips, E Havrdova, A Bar-Or, L
Kappos, H Yuan, P Valencia, L Oliva, M Novas, J
Li, MT Sweetser, NC Kurukulasuriya, V Viglietta,
RJ Fox
P839
14:45 - 16:15
Sat - 9/13
Outside Hall C Late Breaking News Posters Tecfidera DMF protects neural stem/progenitor cells and
differentiated neurons from oxidative damage
through regulating anti-oxidative stress genes
S Chuikov, S Taitano, Q Wu, Y Mao-Draayer LBP14
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 16
Exhibit 15: GSK GSK
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Ofatumumab Follow-up data from the Mirror study: a dose-
ranging study of subcutaneous ofatumumab in
subjects with relapsing-remitting multiple sclerosis
PS Sorenson, ST Kavanagh, DJ Austin, RA
Grove, MC Lopez, JM Tolson, SA Van Meter, A
Bar-Or
P048
●15:30 - 17:00
Fri - 9/12
Small Ballroom
(302-304-306)
Free Communication 2 MOR103 Safety and pharmacokinetics of MOR103, a
human antibody to granulocyte-macrophage
colony-stimulating factor, in patients with multiple
sclerosis
CS Constantinescu, A Asher, W Fryze, W
Kozubski, F Wagner, JJ Aram, R Tanasescu, RP
Korolkiewicz, S Steidl, T Sprenger, WE Radue
FC2.4
●09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion
remyelination in a relapsing remitting MS
population: design of a phase 2a imaging study
C Schwartzbach, R Grove, P Thompson, O Graff,
MA Peykamian, K Harding, J Hilpert, R Brown, D
Arnold
P726
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 17
Exhibit 16: Novartis Novartis
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Gilenya The effects of age and gender on brain volume in
FREEDOMS, FREEDOMS II and TRANSFORMS
phase 3 studies
E-W Radue, JS Wolinsky, D Tomic, DA Häring, P
Chin, F Barkhof
P047
●09:00 - 10:00
Thu - 9/11
Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under
siponimod (BAF312) treatment to infer time to
immune reconstitution
C Sarr, M Savelieva, G Ette, C Petry, E
Legangneux, E Wallström
P050
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Time to brain atrophy is prolonged in continuously
fingolimod-treated MS patients vs placebo or
interferon beta 1-a in phase 3 studies of
fingolimod
D Häring, D Tomic, D Piani Meier, N Sfikas, P
Chin, G Francis
P081
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Safety and tolerability of fingolimod in relapsing-
remitting multiple sclerosis: results from a large
open-label clinical trial
A Laroni, D Brogi, V Brescia Morra, L Guidi, C
Pozzilli, G Comi, A Lugaresi, R Turrini, D
Raimondi, A Uccelli, GL Mancardi, EAP
Investigators
P083
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya An interim analysis of the German START-study
confirms the good cardiac safety profile of
fingolimod
V Limmroth, S Hoyer, M Lang, S Schmidt, T
Ziemssen
P086
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Effect of fingolimod on evolution of baseline
enhancing MRI lesions into persistent T1
hypointense lesions: post hoc analysis of the
FREEDOMS study
EW Radue, T Sprenger, A de Vera, G Francis, E
Rochotte, D Tomic, L Kappos
P101
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya 24 month PANGAEA: a 5-year non-interventional
study of safety, efficacy and pharmacoeconomic
data for fingolimod patients in daily clinical
T Ziemssen, A Fuchs, H-J Schwarz, T van
Lokven, C Cornelissen
P107
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for
MRI lesion counts under siponimod treatment and
its dependence on the effect on lymphocyte
reduction
M Savelieva, E Wallström P109
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Impact of fingolimod on achieving no evidence of
disease activity in pre-treated patients with high
disease activity in FREEDOMS and FREEDOMS
II
N Bergvall, D Tomic, N Sfikas, L Kappos P112
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya vs.
Tecfidera
Persistence with fingolimod versus dimethyl
fumarate in patients with multiple sclerosis:
retrospective analysis of US open source
pharmacy data
N Bergvall, R Lahoz, T Nazareth, JR Korn P289
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Including threshold rates of brain volume loss in
the definition of disease-activity-free in multiple
sclerosis using fingolimod phase 3 data
N De Stefano, T Sprenger, MS Freedman, B
Cree, MP Sormani, DA Häring, G Francis, D Piani
Meier, D Tomic, L Kappos
P290
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Tecfidera vs.
Gilenya
Comparative tolerability and efficacy of dimethyl
fumarate and fingolimod in multiple sclerosis
S Cohn, R Bermel, C Hara, C Hersh, RJ Fox, J
Cohen, D Ontaneda
P300
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Gilenya Sustained low rate of brain volume loss under
long-term fingolimod treatment in relapsing
multiple sclerosis: results from the LONGTERMS
study
EW Radue, F Barkhof, J Cohen, R Gottschalk, Y
Zhang, L Cappiello, P von Rosenstiel, L Kappos
P439
08:15 - 09:15
Fri - 9/12
Small Ballroom
(302-304-306)
Free Communication 2 Gilenya Inclusion of brain volume loss in a revised
measure of multiple sclerosis disease-activity
freedom: the effect of fingolimod
L Kappos, E-W Radue, MS Freedman, B Cree,
MP Sormani, N Sfikas, G Francis, D Tomic, D
Piani Meier, N De Stefano
FC1.5
●15:30 - 17:00
Fri - 9/12
Small Ballroom
(302-304-306)
Free Communication 2 Gilenya Brain volume change by quartile and disability
progression in multiple sclerosis: a 4-year analysis
of the phase 3 FREEDOMS trial and its extension
D Jeffery, E Verdun, D Piani Meier, S Ritter, P
Chin, E-W Radue, W Camu
FC2.3
08:15 - 09:15
Fri - 9/12
Hall C Poster Session 2 Gilenya Identification of tissue-specific MRI markers to
assess protection and repair in response to
fingolimod
C Berrios-Otero, L Fleysher, J Zhang, E
Fieremans, G John, M Inglese
P497
08:15 - 09:15
Fri - 9/12
Hall C Poster Session 2 M356 Comparative efficacy between a generic (M356)
and brand Copaxone® (glatiramer acetate
injection) in an animal model of multiple sclerosis
C Honan, TC Ganguly, I Fier, GV Kaundinya P600
14:45 - 16:15
Sat - 9/13
Outside Hall C Late Breaking News Posters Siponomid Impact of siponimod (BAF 312) on CNS
remyelination in a transgenic Xenopus model
A Mannioui, L Azoyan, D Du Pasquier, B Zalc LBP6
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 18
Exhibit 17: Sanofi Sanofi
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Lemtrada Cost-effectiveness of alemtuzumab vs
subcutaneous interferon beta-1a for treatment of
active relapsing-remitting multiple sclerosis: payer
perspective
C Celestin, GR Cutter, AJ Coles, A Reimers, DH
Margolin, on behalf of the CARE-MS I and II
Investigators
P013
●10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple
sclerosis treated with teriflunomide: subgroup
analyses from the TOPIC phase 3 study
JS Wolinsky, P Truffinet, D Bauer, AE Miller, for
the Investigators of the TOPIC Study and the MRI-
AC in Houston, TX
P040
●10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Lemtrada Efficacy and safety of alemtuzumab in patients
with relapsing-remitting MS who relapsed on prior
therapy: four-year follow-up of the CARE-MS II
study
H-P Hartung, DL Arnold, JA Cohen, AJ Coles, EJ
Fox, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS II Investigators
P043
●10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Lemtrada Alemtuzumab improves quality of life in relapsing-
remitting multiple sclerosis patients who relapsed
on prior therapy: 3-year follow-up of CARE-MS II
T Moreau, DH Margolin, L Kasten, B Singer, on
behalf of the CARE-MS II Investigators
P044
●10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups
defined by prior treatment: pooled analyses of the
phase 3 TEMSO and TOWER studies
MS Freedman, D Dukovic, M Benamor, P
Truffinet, L Kappos
P046
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Aubagio The efficacy of teriflunomide is evident before
steady-state plasma concentrations are reached
JS Wolinsky, D Dukovic, P Truffinet, L Kappos,
for the investigators of the Phase Proof-of-
Concept, TEMSO, TOWER and TOPIC Studies,
and the MRI-AC in Houston, TX
P058
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Aubagio Effect of teriflunomide on lymphocyte and
neutrophil counts: pooled analyses from four
placebo-controlled studies
G Comi, MS Freedman, L Kappos, AE Miller, TP
Olsson, JS Wolinsky, M Benamor, D Dukovic, P
Truffinet, PW O'Connor
P060
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Lemtrada Alemtuzumab improves MRI outcomes regardless
of subgroup versus interferon beta-1a in relapsing-
remitting MS patients who relapsed on prior
therapy
F Barkhof, E Fisher, J Palmer, DH Margolin, DL
Arnold, on behalf of the CARE-MS II Investigators
P075
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Aubagio Long-term MRI outcomes from patients treated
with teriflunomide: results from a phase 2
extension study
DBK Li, AL Traboulsee, P Truffinet, D Dukovic,
PW O’Connor
P079
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Lemtrada Alemtuzumab reduces disease activity in
treatment-naive patients with highly active
relapsing-remitting multiple sclerosis
S Krieger, C Lubetzki, J Palmer, DH Margolin, on
behalf of CARE-MS I Study Investigators
P088
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Lemtrada Efficacy and safety of alemtuzumab in treatment-
naive patients with relapsing-remitting MS: four-
year follow-up of the CARE-MS I study
AJ Coles, DL Arnold, JA Cohen, EJ Fox, H-P
Hartung, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS I Investigators
P090
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Aubagio Efficacy of teriflunomide in patients with early
stage MS: analysis of the TOPIC study using
2010 McDonald diagnostic criteria
JS Wolinsky, P Truffinet, D Bauer, AE Miller, for
the Investigators of the TOPIC Study and the MRI-
AC in Houston, TX
P095
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide
clinical development program
TP Leist, MS Freedman, L Kappos, TP Olsson,
AE Miller, JS Wolinsky, PW O'Connor, M
Benamor, P Truffinet, D Dukovic, G Comi0
P097
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Lemtrada Alemtuzumab improves MRI outcomes in
relapsing-remitting multiple sclerosis patients who
relapsed on prior therapy: three-year follow-up of
E Fisher, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, DL Arnold, on
behalf of the CARE-MS II Investigators
P103
●08:15 - 09:15
Fri - 9/12
Auditorium Free Communication 1 Lemtrada Disease-free outcomes with alemtuzumab: 3-year
follow-up of the CARE-MS studies
E Havrdova, DL Arnold, J Palmer, DH Margolin,
on behalf of CARE-MS I and CARE-MS II Study
Investigators
FC1.4
●15:30 - 17:00
Fri - 9/12
Small Ballroom
(302-304-306)
Free Communication 2 Lemtrada Alemtuzumab improves MRI outcomes in
treatment-naive active relapsing-remitting multiple
sclerosis patients: three-year follow-up from
CARE-MS I
DL Arnold, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, E Fisher, on
behalf of CARE-MS I Investigators
FC2.2
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Lemtrada Defining clinical meaning of patient-reported
outcomes with disability assessment in multiple
sclerosis: an analysis of the CARE-MS II study
L Steinman, H Wang, Y Liu, J Palmer, Q Zhang,
on behalf of the CARE-MS II Investigators
P802
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 Lemtrada Pregnancy outcomes in the alemtuzumab MS
clinical development program
P McCombe, A Achiron, DH Margolin, J Palmer, P
Oyuela, on behalf of the CAMMS, CARE-MS I,
and CARE-MS II Investigators
P842
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 19
Exhibit 18: Teva Teva
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Hall C Poster Session 1 Laquinimod Effect of laquinimod on gray matter and white
matter atrophy in relapsing-remitting multiple
sclerosis: analysis of the BRAVO phase III trial
K Nakamura, TL Vollmer, T Gorfine, V Knappertz,
DL Arnold
P041
●14:00 - 15:30
Thu - 9/11
Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of
glatiramer acetate 40mg/mL TIW and 20mg/mL
QD: results of a systematic review and meta-
analysis
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P053
14:00 - 15:30
Thu - 9/11
Hall C Poster Session 1 Laquinimod Switching from interferon β-1a IM to laquinimod:
safety and efficacy results from the BRAVO study
extension
TL Vollmer, N Ashtamker, Y Sidi, D Ladkani, T
Gorfine, PS Sørensen
P054
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Laquinimod Consistent effect of laquinimod on relapse-related
and disability progression-related endpoints
G Comi, TL Vollmer, L Kappos, X Montalban, T
Gorfine, N Sasson, V Knappertz,
P061
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in
worsening relapsing-remitting multiple sclerosis
defined by baseline EDSS over 3
TL Vollmer, G Comi, L Kappos, X Montalban, G
Cutter, JR Steinerman, N Sasson, T Gorfine, V
Knappertz,
P062
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Laquinimod Laquinimod effect on confirmed disability
progression: minimal mediation by relapse or T2
lesions reduction
MP Sormani, TL Vollmer, G Comi, Y Sidi, JR
Steinerman, T Gorfine, V Knappertz,
P069
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Laquinimod Laquinimod disability progression effects are
maintained with increasingly rigorous confirmation
time intervals
G Comi, TL Vollmer, L Kappos, X Montalban, N
Sasson, T Gorfine, V Knappertz,
P070
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Laquinimod Temporal pattern of laboratory changes with
laquinimod treatment
TL Vollmer, G Comi, PS Sørensen, N Sasson, T
Gorfine, V Knappertz,
P071
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Copaxone TIW Convenience of glatiramer acetate 40mg/mL three
times weekly: evidence from the GLACIER study
JS Wolinsky, TE Borresen, DW Dietrich, BF
Gilder, Y Sidi, JR Steinerman, V Knappertz, S
Kolodny, GLACIER Study Group
P080
●
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate
40mg/mL TIW and 20mg/mL QD dosing regimen
effects on relapse rate: results of a predictive
statistical model
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P100
●15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site
reactions with glatiramer acetate 40mg/mL three
times weekly dosing
JS Wolinsky, Y Sidi, JR Steinerman, V Knappertz,
S Kolodny, The GLACIER Study Group
P306
●
15:30 - 17:00
Fri - 9/12
Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to
copaxone on efficacy and safety: results of the
randomized double-blind GATE trial in multiple
sclerosis
JA Cohen, A Belova, K Selmaj, C Wolf, JJL
Oberyé, ERW van den Tweel, NP Koper, G
Voortman, F Barkhof, on behalf of the GATE
Study Group
FC1.2
08:15 - 09:15
Fri - 9/12
Auditorium Free Communication 1 Laquinimod Long-term follow-up of laquinimod in patients with
relapsing-remitting multiple sclerosis
G Comi, TL Vollmer, N Ashtamker, Y Sidi, D
Ladkani, T Gorfine, PS Sørensen
FC1.3
●15:30 - 17:00
Fri - 9/12
Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized
safety/tolerability study of glatiramer acetate
40mg/mL three times weekly versus 20mg/mL
daily in RRMS
JS Wolinsky, DW Dietrich, TE Borresen, BF
Gilder, JR Steinerman, Y Sidi, A Vainstein, S
Kolodny, V Knappertz, GLACIER Study Group
FC3.2
15:30 - 17:00
Fri - 9/12
Grand Ballroom Free Communication 3 Copaxone + Estriol A combination trial of estriol plus glatiramer
acetate in relapsing-remitting multiple sclerosis:
effect on disabilities
R Voskuhl, H Wang, G Lee, B Giesser, CH Tse, R
Elashoff, Estriol Relapse Trial Study Group
FC3.3
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 20
Exhibit 19: Receptos Receptos
Key? Time Room Type Drug Title Authors ID
●14:45 - 16:15
Sat - 9/13
Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a
randomized, double-blind, placebo-controlled trial
of oral RPC1063 in relapsing multiple sclerosis
J Cohen, DL Arnold, G Comi, A Bar-Or, S
Gujrathi, JP Hartung, A Olson, M Cravets, PA
Frohna, K Selmaj
LB1.1
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 21
Exhibit 20: XenoPort Xenoport
Key? Time Room Type Drug Title Authors ID
●
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood
lymphocyte responses in healthy subjects dosed
with XP23829, a novel fumaric acid ester for
multiple sclerosis
L Steinman, RJ Fox, D Lissin, L Clark, K Cundy P958
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 22
Exhibit 21: Other Other
Key? Time Room Type Drug Title Authors ID
10:00 - 11:30
Thu - 9/11
Auditorium Parallel Session 1: Cell-based
Therapies
MSCs Phase I trial of intravenous autologous culture-
expanded mesenchymal stem cell transplantation
in multiple sclerosis
JA Cohen, PB Imrey, SM Planchon, RA Bermel, E
Fisher, RJ Fox, A Bar-Or, SL Sharp, TT
Skaramagas, P Jagodnik, M Karafa, S Morrison, J
Reese Koc, SL Gerson, HM Lazarus
PS1.5
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 2B3-201 Double-blind, placebo- and active comparator-
controlled study in healthy males to assess the
safety, pharmacokinetics and -dynamics of 2B3-
201
W Gladdines, K Kanhai, I Stavrakaki, RGJA
Zuiker, PJ Gaillard, GJ Groeneveld, F Lönnqvist
P076
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Alpha B-Crystallin A randomized, double-blind, placebo-controlled
phase IIa study of alpha B-crystallin in multiple
sclerosis
JM van Noort, M Bsibsi, PJ Nacken, R Verbeek,
EH Venneker
P082
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 GNbAC1 GNbAC1, a monoclonal antibody against the
MSRV envelope protein, pharmacodynamic
responses in patients with multiple sclerosis
F Curtin P092
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 NKT Cell Ligand
OCH
First-in-human phase 1 study of invariant NKT cell
ligand OCH
D Noto, M Araki, W Sato, T Okamoto, M Murata,
S Miyake, T Yamamura,
P093
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 Copaxone +
Interferon Beta-1a
Physician and participant treatment guesses in
the double-blind CombiRx study
SS Cofield, T Gustafson, GR Cutter, JS Wolinsky,
FD Lublin, The CombiRx Investigators
P099
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 MIS416 Innate immune modulator MIS416 enhances
systemic levels of negative regulators of
inflammation in phase 2a clinical trial plasma
samples
G Webster, V Pearson, R Girvan P111
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 MIF Inhibitor A novel MIF inhibitor as therapy for multiple
sclerosis and stroke
AA Vandenbark, R Meza-Romero, G Benedek, H
Offner,
P310
15:30 - 17:00
Thu - 9/11
Hall C Poster Session 1 HPP971 The novel Bach1 inhibitor HPP971 uniquely
activates Nrf2 and reduces disease severity in a
mouse model of experimental autoimmune
encephalomyelitis
S-K Kim, J Kassis, O Attucks, J Freeman, Z
Zhong, S Gupta, S Victory, D Polisetti, A Mjalli, R
Andrews, M Kostura, M Guzel, B Gaddam, S
Weaver, K Sakmann, ST Davis
P396
08:15 - 09:15
Fri - 9/12
Small Ballroom
(302-304-306)
Parallel Session 10: Immune
mechanisms
Copaxone +
Interferon Beta-1a
Early on-treatment T2 and T1 subtraction MRI
predicts imaging and clinical outcomes in the
CombiRx cohort
F Lalys, L Freeman, TD Staewen, JA Lincoln, F
Nelson, S Datta, PA Narayana, SS Cofield, T
Gustafson, GR Cutter, FD Lublin, JS Wolinsky,
CombiRx Investigators
PS9.6
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 NDC-1308 NDC-1308, a gain of function estradiol analog for
inducing remyelination in multiple sclerosis
patients
SH Nye, S Medicetty, BD Trapp, JG Yarger P710
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 Anti-SEMA4D mAb Anti- SEMA4D antibody ameliorates pathogenic
processes related to multiple sclerosis
AS Jonason, E Klimatcheva, T Fisher, C Reilly, L
Winter, J Veeraraghavan, M Doherty, C Mallow, J
Seils, H Bussler, S Torno, R Kirk, A Howell, M
Scrivens, L Balch, T Pandina, W Wang, E Evans,
WJ Bowers, M Paris, J Leonard, V Iddison, E
Smith, M Zauderer
P712
09:45 - 11:15
Fri - 9/12
Hall C Poster Session 2 KB3944 KB3944, a selective estrogen receptor beta
agonist, in preclinical development for
neuroprotective and regenerative therapy of
multiple sclerosis
P Fagergren, S Tiwari-Woodruff, M Osterlund P715
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 MSCs Cytogenetic analysis of culture-expanded human
mesenchymal stem cells used in a phase I clinical
trial in multiple sclerosis
SM Planchon, I Warshawsky, JS Reese, KM
Drake, JA Cohen
P890
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 MSCs Immune function monitoring in a phase I trial of
autologous culture-expanded mesenchymal stem
cell transplantation for relapsing multiple sclerosis
A Bar-Or, M-N Boivin, A Rozenberg, T Johnson, C
Belabani, G Morisse, J Sirois, S Lai Wing Sun, S
Vanamala, A Del Rosario Villalobos, J Reese Koc,
S Morrison, RA Bermel, PB Imrey, SM Planchon,
JA Cohen
P892
14:45 - 16:15
Fri - 9/12
Hall C Poster Session 2 ACTiMuS Assessment of bone marrow-derived cell therapy
in progressive multiple sclerosis (ACTiMuS)
CM Rice, DI Marks, Y Ben-Shlomo, N Evangelou,
C Metcalfe, P Walsh, DA Cottrell, NM Kane, A
Wilkins, NJ Scolding
P902
14:45 - 16:15
Sat - 9/13
Outside Hall C Late Breaking News Posters GNbAC1 HERV-W envelope protein inhibits
oligodendroglial cell differentiation which can be
abrogated by the neutralizing antibody GNbAC1
D Kremer, M Foerster, T Schichel, P Goettle, H-P
Hartung, H Perron, P Kuery
LBP15
14:45 - 16:15
Sat - 9/13
Outside Hall C Late Breaking News Posters GNbAC1 Follow-up of MS patients from phase IIa clinical
study of GNbAC1 reveals unexpected decrease of
HERV-W endogenous retrovirus genes
expression
R Faucard, A Madeira, N Gehin, T Derfuss, H-P
Hartung, R Du Pasquier, L Kappos, P Lalive, H
Porchet, AB Lang, F Curtin, HJF Perron
LBP16
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 23
All Sessions
Exhibit 22: Wednesday – September 10, 2014 Wednesday - September 10, 2014
Key? Time Location Type Drug Title Authors ID
08:00 - 09:30 304 Teaching Course 1: Current
controversy in management:
Interactive case discussion
General Current controversy in management: interactive
case discussion
AE Miller TC1.1
08:00 - 09:30 312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General Treating CIS and early RRMS: pros and cons A Goodyear TC2.1
●08:00 - 09:30 312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General Choosing the right treatment for the right patient RJ Fox TC2.2
●08:00 - 09:30 312 Teaching Course 2: How do I
choose the correct disease-
modifying treatment?
General When and how should MS treatment be switched
or escalated
BC Kieseier TC2.3
08:00 - 09:30 310 Teaching Course 3: Symptom
management
General Symptom management - focus on gait impairment A Goodman TC3.1
08:00 - 09:30 310 Teaching Course 3: Symptom
management
General Effective management of spasticity AJ Thompson TC3.2
08:00 - 09:30 310 Teaching Course 3: Symptom
management
General Exercise therapy as symptomatic treatment U Dalgas TC3.3
08:00 - 09:30 313 Teaching Course 5: Clinically
isolated syndromes (CIS)
General Radiologically isolated syndrome: pre-
symptomatic MS?
DT Okuda TC5.1
08:00 - 09:30 313 Teaching Course 5: Clinically
isolated syndromes (CIS)
General How can we treat and manage CIS patients? M Tintore TC5.3
●08:00 - 09:30 306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Optic nerve imaging: pathophysiological insights A Toosy TC7.1
●08:00 - 09:30 306 Teaching Course 7: Imaging small
parts of the nervous system
(MAGNIMS)
General Deep grey matter: current and new technologies MA Rocca TC7.2
10:00 - 11:30 310 Teaching Course 8: Update in
pediatric MS
General Diagnosis of MS and acute demyelinating
disorders in children
C Hemingway TC8.1
10:00 - 11:30 310 Teaching Course 8: Update in
pediatric MS
General Emerging therapies and clinical trials in pediatric
MS
T Chitnis TC8.2
10:00 - 11:30 310 Teaching Course 8: Update in
pediatric MS
General MRI: role in assessment of MS disease activity
and disease impact in patients with MS onset
during childhood
BL Banwell TC8.3
●10:00 - 11:30 312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Diagnostic approach to MS P Vermersch TC9.1
●10:00 - 11:30 312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General Red flags in MS: zebras or horses? S Galetta TC9.2
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 24
Exhibit 23: Wednesday – September 10, 2014 Wednesday - September 10, 2014
Key? Time Location Type Drug Title Authors ID
10:00 - 11:30 312 Teaching Course 9: Differential
diagnoses and diagnostic dilemmas
General MS differential diagnoses E Waubant TC9.3
10:00 - 11:30 302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Inadequate activation of T cells in MS: possible
mechanisms involved
RS LIBLAU TC10.1
10:00 - 11:30 302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Contribution of B cell: T cell interactions to CNS
inflammation in MS
A Bar-Or TC10.2
10:00 - 11:30 302 Teaching Course 10:
Neuroimmunology in relation to MS
pathophysiology and
immunotherapy
General Immune cell trafficking to the CNS, mechanisms
and therapeutic implications
MH Han TC10.3
●10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Lesions: can we go beyond counts and volumes? N De Stefano TC11.1
●10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Brain atrophy: an outcome measure in clinical
studies
E Fisher TC11.2
●10:00 - 11:30 311 Teaching Course 11: MRI issues in
clinical practice (MAGNIMS)
General Imaging biomarkers of normal-appearing brain D Pelletier TC11.3
10:00 - 11:30 313 Teaching Course 12: Neuro-
opthalmology update
General Visual manifestations of CNS demyelinating
disorders
FE Costello TC12.1
10:00 - 11:30 313 Teaching Course 12: Neuro-
opthalmology update
General The role of visual outcomes in MS clinical trials LJ Balcer TC12.3
●10:00 - 11:30 304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Assessing drug efficacy: challenges in study
design
F Lublin TC13.1
10:00 - 11:30 304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Assessing treatment efficacy in MS: observational
studies vs clinical trials
MP Sormani TC13.2
●10:00 - 11:30 304 Teaching Course 13: Assessing the
drug efficacy: Challenges in study
design
General Investigator initiated vs industry sponsored
studies, which and when - randomized trials in the
active treatment era
GR Cutter TC13.3
10:00 - 11:30 306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General The manifestations of cognitive and psychiatric
disorders in MS and assessment strategies
R Benedict TC14.1
10:00 - 11:30 306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General Treatment of disorders of mood and affect in MS
patients
A Feinstein TC14.2
10:00 - 11:30 306 Teaching Course 14:
Neuropsychiatric manifestations and
cognitive impairment
General Treatment of cognitive dysfunction in MS patients MP Amato TC14.3
●17:30 - 18:30 Auditorium Satellite Symposium Satellite
Symposium
Emerging Trends in MS Pathophysiology: The
Role of Mitochondria
Sanofi - - - - -
●18:45 - 19:45 Auditorium Satellite Symposium Satellite
Symposium
Beyond Diagnosis: The Essential Role of MRI in
Clinical Management of Multiple Sclerosis
Biogen Idec - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 25
Exhibit 24: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
●
07:15 - 08:15 Auditorium Satellite Symposium Satellite
Symposium
Aligning Treatment Selection With Goals in
Multiple Sclerosis: How Can We Optimized
Established and Emerging Therapy in Clinical
Practice
Sanofi - - - - -
●09:00 - 10:00 Auditorium Plenary Session 1 General Approaching the cause of multiple sclerosis DA Hafler PL1.1
●10:30 - 12:00 Auditorium Parallel Session 1: Cell-based
Therapies
General Assessing myelin repair in multiple sclerosis: Is
imaging useful? Usable? Are we there yet?
C Laule PS1.2
10:30 - 12:00 Auditorium Parallel Session 1: Cell-based
Therapies
MSCs Phase I trial of intravenous autologous culture-
expanded mesenchymal stem cell transplantation
in multiple sclerosis
JA Cohen, PB Imrey, SM Planchon, RA Bermel, E
Fisher, RJ Fox, A Bar-Or, SL Sharp, TT
Skaramagas, P Jagodnik, M Karafa, S Morrison, J
Reese Koc, SL Gerson, HM Lazarus
PS1.5
●12:30 - 13:30 Auditorium Satellite Symposium Satellite
Symposium
Time for change: Advancing our understanding of
MS
Novartis - - - - -
14:00 - 15:30 Small Ballroom
(302-304-306)
Parallel Session 4: EAE and other
animal models
General What can EAE teach us about MS? JM Goverman, MC Johnson, ER Pierson, SB
Simmons
PS4.1
14:00 - 15:30 Auditorium Parallel Session 6: Risk
management with MS Therapy
General PML with novel immunotherapies: Is there light at
the end of the tunnel?
R Gold PS6.1
15:30 - 17:00 Hall C Poster Session 1 Ampyra Treatment patterns and budget impact of
dalfampridine in multiple sclerosis: a retrospective
claims database analysis
S Palli, M Sidovar, M Grabner, A Guo P010
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Cost-effectiveness of alemtuzumab vs
subcutaneous interferon beta-1a for treatment of
active relapsing-remitting multiple sclerosis: payer
perspective
C Celestin, GR Cutter, AJ Coles, A Reimers, DH
Margolin, on behalf of the CARE-MS I and II
Investigators
P013
●15:30 - 17:00 Hall C Poster Session 1 Aubagio MRI outcomes in patients with early multiple
sclerosis treated with teriflunomide: subgroup
analyses from the TOPIC phase 3 study
JS Wolinsky, P Truffinet, D Bauer, AE Miller, for
the Investigators of the TOPIC Study and the MRI-
AC in Houston, TX
P040
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Effect of laquinimod on gray matter and white
matter atrophy in relapsing-remitting multiple
sclerosis: analysis of the BRAVO phase III trial
K Nakamura, TL Vollmer, T Gorfine, V Knappertz,
DL Arnold
P041
●15:30 - 17:00 Hall C Poster Session 1 Plegridy Peginterferon beta-1a may improve recovery
following relapses: data from the 2-year
ADVANCE relapsing-remitting multiple sclerosis
study
BC Kieseier, TF Scott, SD Newsome, SI Sheikh,
S Hung, X You, B Sperling
P042
●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in patients
with relapsing-remitting MS who relapsed on prior
therapy: four-year follow-up of the CARE-MS II
study
H-P Hartung, DL Arnold, JA Cohen, AJ Coles, EJ
Fox, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS II Investigators
P043
●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves quality of life in relapsing-
remitting multiple sclerosis patients who relapsed
on prior therapy: 3-year follow-up of CARE-MS II
T Moreau, DH Margolin, L Kasten, B Singer, on
behalf of the CARE-MS II Investigators
P044
●15:30 - 17:00 Hall C Poster Session 1 Aubagio Evaluating the effect of teriflunomide in subgroups
defined by prior treatment: pooled analyses of the
phase 3 TEMSO and TOWER studies
MS Freedman, D Dukovic, M Benamor, P
Truffinet, L Kappos
P046
15:30 - 17:00 Hall C Poster Session 1 Gilenya The effects of age and gender on brain volume in
FREEDOMS, FREEDOMS II and TRANSFORMS
phase 3 studies
E-W Radue, JS Wolinsky, D Tomic, DA Häring, P
Chin, F Barkhof
P047
15:30 - 17:00 Hall C Poster Session 1 Ofatumumab Follow-up data from the Mirror study: a dose-
ranging study of subcutaneous ofatumumab in
subjects with relapsing-remitting multiple sclerosis
PS Sorenson, ST Kavanagh, DJ Austin, RA
Grove, MC Lopez, JM Tolson, SA Van Meter, A
Bar-Or
P048
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 26
Exhibit 25: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
●15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling dose-PK-lymphocytes relationship under
siponimod (BAF312) treatment to infer time to
immune reconstitution
C Sarr, M Savelieva, G Ette, C Petry, E
Legangneux, E Wallström
P050
●
15:30 - 17:00 Hall C Poster Session 1 Daclizumab Brain MRI results of DECIDE: a randomized,
double-blind trial of DAC HYP vs. IFNβ-1a in
RRMS patients
DL Arnold, L Kappos, E Havrdova, K Selmaj, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
P051
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Effect of bismuth subsalicylate on gastrointestinal
events associated with delayed-release dimethyl
fumarate: a double-blind, placebo-controlled study
C Tornatore, J Li, TS Ma, C von Hehn, J Walsh, J
Zambrano
P052
●15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Comparable clinical and MRI efficacy of
glatiramer acetate 40mg/mL TIW and 20mg/mL
QD: results of a systematic review and meta-
analysis
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P053
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Switching from interferon β-1a IM to laquinimod:
safety and efficacy results from the BRAVO study
extension
TL Vollmer, N Ashtamker, Y Sidi, D Ladkani, T
Gorfine, PS Sørensen
P054
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Delayed-release dimethyl fumarate and disability
assessed by the multiple sclerosis functional
composite: integrated analysis of DEFINE and
CONFIRM
G Giovannoni, R Gold, L Kappos, DL Arnold, A
Bar-Or, NC Kurukulasuriya, M Yang, SP Sarda
P057
15:30 - 17:00 Hall C Poster Session 1 Aubagio The efficacy of teriflunomide is evident before
steady-state plasma concentrations are reached
JS Wolinsky, D Dukovic, P Truffinet, L Kappos,
for the investigators of the Phase Proof-of-
Concept, TEMSO, TOWER and TOPIC Studies,
and the MRI-AC in Houston, TX
P058
●
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in relapsing-remitting multiple sclerosis:
MRI outcomes from DEFINE, CONFIRM, and
ENDORSE
DL Arnold, RJ Fox, R Gold, E Havrdova, L
Kappos, T Yousry, D MacManus, R Zhang, M
Yang, NC Kurukulasuriya, V Viglietta
P059
15:30 - 17:00 Hall C Poster Session 1 Aubagio Effect of teriflunomide on lymphocyte and
neutrophil counts: pooled analyses from four
placebo-controlled studies
G Comi, MS Freedman, L Kappos, AE Miller, TP
Olsson, JS Wolinsky, M Benamor, D Dukovic, P
Truffinet, PW O'Connor
P060
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Consistent effect of laquinimod on relapse-related
and disability progression-related endpoints
G Comi, TL Vollmer, L Kappos, X Montalban, T
Gorfine, N Sasson, V Knappertz,
P061
●15:30 - 17:00 Hall C Poster Session 1 Laquinimod Clinical efficacy of laquinimod 0.6mg once-daily in
worsening relapsing-remitting multiple sclerosis
defined by baseline EDSS over 3
TL Vollmer, G Comi, L Kappos, X Montalban, G
Cutter, JR Steinerman, N Sasson, T Gorfine, V
Knappertz,
P062
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Long-term efficacy of delayed-release dimethyl
fumarate in newly diagnosed patients with RRMS:
an integrated analysis of DEFINE, CONFIRM, and
ENDORSE
R Gold, G Giovannoni, JT Phillips, RJ Fox, A
Zhang, NC Kurukulasuriya
P064
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate for
RRMS in prior interferon users in the DEFINE and
CONFIRM studies
Ó Fernández, G Giovannoni, RJ Fox, R Gold, JT
Phillips, M Okwuokenye, A Zhang, NC
Kurukulasuriya
P065
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Long-term follow-up of the safety of delayed-
release dimethyl fumarate in RRMS: interim
results from the ENDORSE extension study
C Pozzilli, JT Phillips, RJ Fox, K Selmaj, R Zhang,
M Novas, MT Sweetser, R Gold
P066
●15:30 - 17:00 Hall C Poster Session 1 Plegridy Effect of peginterferon beta-1a on MRI measures
and freedom from measured disease activity: 2-
year results from the phase 3 ADVANCE study
DL Arnold, PA Calabresi, BC Kieseier, SI Sheikh,
A Deykin, S Liu, X You, B Sperling, S Hung
P067
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 27
Exhibit 26: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Laquinimod effect on confirmed disability
progression: minimal mediation by relapse or T2
lesions reduction
MP Sormani, TL Vollmer, G Comi, Y Sidi, JR
Steinerman, T Gorfine, V Knappertz,
P069
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Laquinimod disability progression effects are
maintained with increasingly rigorous confirmation
time intervals
G Comi, TL Vollmer, L Kappos, X Montalban, N
Sasson, T Gorfine, V Knappertz,
P070
15:30 - 17:00 Hall C Poster Session 1 Laquinimod Temporal pattern of laboratory changes with
laquinimod treatment
TL Vollmer, G Comi, PS Sørensen, N Sasson, T
Gorfine, V Knappertz,
P071
15:30 - 17:00 Hall C Poster Session 1 Tysabri Quantifying the effect of natalizumab on the total
disability burden of MS patients in AFFIRM using
an exploratory area under the curve analysis
RA Rudick, S Shang, Q Dong, D Paes, D Mikol, S
Belachew
P073
●15:30 - 17:00 Hall C Poster Session 1 Plegridy Impact of peginterferon beta-1a treatment and
disease factors on risk of physical deterioration in
patients with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P074
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes regardless
of subgroup versus interferon beta-1a in relapsing-
remitting MS patients who relapsed on prior
therapy
F Barkhof, E Fisher, J Palmer, DH Margolin, DL
Arnold, on behalf of the CARE-MS II Investigators
P075
15:30 - 17:00 Hall C Poster Session 1 2B3-201 Double-blind, placebo- and active comparator-
controlled study in healthy males to assess the
safety, pharmacokinetics and -dynamics of 2B3-
201
W Gladdines, K Kanhai, I Stavrakaki, RGJA
Zuiker, PJ Gaillard, GJ Groeneveld, F Lönnqvist
P076
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Lymphocyte count reductions with delayed-
release dimethyl fumarate: integrated analysis of
the phase 2, phase 3, and extension studies
RJ Fox, A Chan, R Gold, JT Phillips, K Selmaj, R
Zhang, H Yuan, M Novas, V Viglietta, NC
Kurukulasuriya
P077
15:30 - 17:00 Hall C Poster Session 1 Aubagio Long-term MRI outcomes from patients treated
with teriflunomide: results from a phase 2
extension study
DBK Li, AL Traboulsee, P Truffinet, D Dukovic,
PW O’Connor
P079
15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Convenience of glatiramer acetate 40mg/mL three
times weekly: evidence from the GLACIER study
JS Wolinsky, TE Borresen, DW Dietrich, BF
Gilder, Y Sidi, JR Steinerman, V Knappertz, S
Kolodny, GLACIER Study Group
P080
15:30 - 17:00 Hall C Poster Session 1 Gilenya Time to brain atrophy is prolonged in continuously
fingolimod-treated MS patients vs placebo or
interferon beta 1-a in phase 3 studies of
fingolimod
D Häring, D Tomic, D Piani Meier, N Sfikas, P
Chin, G Francis
P081
15:30 - 17:00 Hall C Poster Session 1 Alpha B-Crystallin A randomized, double-blind, placebo-controlled
phase IIa study of alpha B-crystallin in multiple
sclerosis
JM van Noort, M Bsibsi, PJ Nacken, R Verbeek,
EH Venneker
P082
15:30 - 17:00 Hall C Poster Session 1 Gilenya Safety and tolerability of fingolimod in relapsing-
remitting multiple sclerosis: results from a large
open-label clinical trial
A Laroni, D Brogi, V Brescia Morra, L Guidi, C
Pozzilli, G Comi, A Lugaresi, R Turrini, D
Raimondi, A Uccelli, GL Mancardi, EAP
Investigators
P083
●15:30 - 17:00 Hall C Poster Session 1 Plegridy Safety and tolerability of peginterferon beta-1a in
patients with relapsing-remitting multiple sclerosis:
2-year data from the ADVANCE study
BC Kieseier, PA Calabresi, Y Cui, Y Zhu, S Hung,
A Deykin, A Seddighzadeh
P085
15:30 - 17:00 Hall C Poster Session 1 Gilenya An interim analysis of the German START-study
confirms the good cardiac safety profile of
fingolimod
V Limmroth, S Hoyer, M Lang, S Schmidt, T
Ziemssen
P086
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 28
Exhibit 27: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab reduces disease activity in
treatment-naive patients with highly active
relapsing-remitting multiple sclerosis
S Krieger, C Lubetzki, J Palmer, DH Margolin, on
behalf of CARE-MS I Study Investigators
P088
15:30 - 17:00 Hall C Poster Session 1 Betaseron Interferon beta-1b in treatment-naïve paediatric
patients with relapsing-remitting MS: baseline
data from the BETAPAEDIC study
J Gärtner, W Brück, A Weddige, K Reinhardt, JP
Bugge, The BETAPAEDIC Study Group
P089
●
15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Efficacy and safety of alemtuzumab in treatment-
naive patients with relapsing-remitting MS: four-
year follow-up of the CARE-MS I study
AJ Coles, DL Arnold, JA Cohen, EJ Fox, H-P
Hartung, E Havrdova, KW Selmaj, DH Margolin, J
Palmer, P Oyuela, MA Panzara, DAS Compston,
on behalf of the CARE-MS I Investigators
P090
15:30 - 17:00 Hall C Poster Session 1 GNbAC1 GNbAC1, a monoclonal antibody against the
MSRV envelope protein, pharmacodynamic
responses in patients with multiple sclerosis
F Curtin P092
15:30 - 17:00 Hall C Poster Session 1 NKT Cell Ligand
OCH
First-in-human phase 1 study of invariant NKT cell
ligand OCH
D Noto, M Araki, W Sato, T Okamoto, M Murata,
S Miyake, T Yamamura,
P093
●
15:30 - 17:00 Hall C Poster Session 1 Daclizumab Safety and tolerability of daclizumab HYP
treatment in relapsing-remitting multiple sclerosis:
results of the DECIDE study
K Selmaj, L Kappos, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, K Riester, M Sweetser,
J Elkins
P094
15:30 - 17:00 Hall C Poster Session 1 Aubagio Efficacy of teriflunomide in patients with early
stage MS: analysis of the TOPIC study using
2010 McDonald diagnostic criteria
JS Wolinsky, P Truffinet, D Bauer, AE Miller, for
the Investigators of the TOPIC Study and the MRI-
AC in Houston, TX
P095
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Differential recovery from relapse between
treatment groups in the CONFIRM study of
delayed-release dimethyl fumarate
A Chan, JT Phillips, RJ Fox, A Zhang, M
Okwuokenye, NC Kurukulasuriya
P096
●15:30 - 17:00 Hall C Poster Session 1 Aubagio Pooled safety analyses from the teriflunomide
clinical development program
TP Leist, MS Freedman, L Kappos, TP Olsson,
AE Miller, JS Wolinsky, PW O'Connor, M
Benamor, P Truffinet, D Dukovic, G Comi0
P097
15:30 - 17:00 Hall C Poster Session 1 Copaxone +
Interferon Beta-1a
Physician and participant treatment guesses in
the double-blind CombiRx study
SS Cofield, T Gustafson, GR Cutter, JS Wolinsky,
FD Lublin, The CombiRx Investigators
P099
●
15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Indirect comparison of glatiramer acetate
40mg/mL TIW and 20mg/mL QD dosing regimen
effects on relapse rate: results of a predictive
statistical model
G Cutter, JS Wolinsky, G Comi, D Ladkani, V
Knappertz, A Vainstein, N Sasson, O Khan,
P100
15:30 - 17:00 Hall C Poster Session 1 Gilenya Effect of fingolimod on evolution of baseline
enhancing MRI lesions into persistent T1
hypointense lesions: post hoc analysis of the
FREEDOMS study
EW Radue, T Sprenger, A de Vera, G Francis, E
Rochotte, D Tomic, L Kappos
P101
15:30 - 17:00 Hall C Poster Session 1 Rebif No evident disease activity at 24 weeks in patients
with relapsing MS treated with interferon β-1a SC
vs. interferon β-1a IM in the EVIDENCE study
PK Coyle, J Fang, A Hassan, C Cha, F Dangond,
AT Reder
P102
●15:30 - 17:00 Hall C Poster Session 1 Alemtuzumab Alemtuzumab improves MRI outcomes in
relapsing-remitting multiple sclerosis patients who
relapsed on prior therapy: three-year follow-up of
E Fisher, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, DL Arnold, on
behalf of the CARE-MS II Investigators
P103
15:30 - 17:00 Hall C Poster Session 1 Rebif No evident disease activity in relapsing MS
patients treated with interferon β-1a SC vs.
interferon β-1a IM: subgroup analyses of the
EVIDENCE study
PK Coyle, J Fang, A Hassan, C Cha, F Dangond,
AT Reder
P104
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 29
Exhibit 28: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
●15:30 - 17:00 Hall C Poster Session 1 Daclizumab Integrated analysis of daclizumab HYP
pharmacokinetics from three phase 1 studies
AA Othman, JQ Tran, MT Tang, S Dutta P106
15:30 - 17:00 Hall C Poster Session 1 Gilenya 24 month PANGAEA: a 5-year non-interventional
study of safety, efficacy and pharmacoeconomic
data for fingolimod patients in daily clinical
T Ziemssen, A Fuchs, H-J Schwarz, T van
Lokven, C Cornelissen
P107
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Efficacy of delayed-release dimethyl fumarate in
multiple sclerosis patients with moderate
disability: an integrated analysis of the phase 3
studies
M Hutchinson, A Zhang, M Yang, M Okwuokenye,
NC Kurukulasuriya, RJ Fox, R Gold
P108
●
15:30 - 17:00 Hall C Poster Session 1 Siponimod Modeling concentration-efficacy relationship for
MRI lesion counts under siponimod treatment and
its dependence on the effect on lymphocyte
reduction
M Savelieva, E Wallström P109
●
15:30 - 17:00 Hall C Poster Session 1 Tecfidera Five-year follow-up of delayed-release dimethyl
fumarate in RRMS: integrated clinical efficacy
data from the DEFINE, CONFIRM, and
ENDORSE studies
R Gold, JT Phillips, A Bar-Or, M Hutchinson, L
Kappos, R Zhang, M Yang, NC Kurukulasuriya, V
Viglietta, RJ Fox
P110
15:30 - 17:00 Hall C Poster Session 1 MIS416 Innate immune modulator MIS416 enhances
systemic levels of negative regulators of
inflammation in phase 2a clinical trial plasma
samples
G Webster, V Pearson, R Girvan P111
15:30 - 17:00 Hall C Poster Session 1 Gilenya Impact of fingolimod on achieving no evidence of
disease activity in pre-treated patients with high
disease activity in FREEDOMS and FREEDOMS
II
N Bergvall, D Tomic, N Sfikas, L Kappos P112
15:30 - 17:00 Hall C Poster Session 1 Tysabri Natalizumab decreases progression of disability in
RRMS patients as measured by the composite
EDSS-Plus in AFFIRM
Q Dong, RA Rudick, D Paes, D Mikol, S Belachew P113
●15:30 - 17:00 Hall C Poster Session 1 BIIB033 Potential biomarkers of BIIB033 activity in phase 1
clinical studies
S Ray, J Tran, S Ciotti, Q Duong, R Huang, L
Yang, D Cadavid
P262
●
15:30 - 17:00 Hall C Poster Session 1 Gilenya vs.
Tecfidera
Persistence with fingolimod versus dimethyl
fumarate in patients with multiple sclerosis:
retrospective analysis of US open source
pharmacy data
N Bergvall, R Lahoz, T Nazareth, JR Korn P289
15:30 - 17:00 Hall C Poster Session 1 Gilenya Including threshold rates of brain volume loss in
the definition of disease-activity-free in multiple
sclerosis using fingolimod phase 3 data
N De Stefano, T Sprenger, MS Freedman, B
Cree, MP Sormani, DA Häring, G Francis, D Piani
Meier, D Tomic, L Kappos
P290
15:30 - 17:00 Hall C Poster Session 1 Tecfidera vs.
Gilenya
Comparative tolerability and efficacy of dimethyl
fumarate and fingolimod in multiple sclerosis
S Cohn, R Bermel, C Hara, C Hersh, RJ Fox, J
Cohen, D Ontaneda
P300
15:30 - 17:00 Hall C Poster Session 1 General Time to relapse among propensity score matched
patients receiving disease modifying therapy for
multiple sclerosis
BH Johnson, MM Bonafede, C Watson P304
●15:30 - 17:00 Hall C Poster Session 1 Copaxone TIW Reduced frequency and severity of injection site
reactions with glatiramer acetate 40mg/mL three
times weekly dosing
JS Wolinsky, Y Sidi, JR Steinerman, V Knappertz,
S Kolodny, The GLACIER Study Group
P306
15:30 - 17:00 Hall C Poster Session 1 General Real-world titration of disease modifying therapies
in the treatment of multiple sclerosis: findings
from a survey of neurologists
T Nazareth, J Marvel, S Sikirica, J Xie, W
Reichmann, C Zhao, R Sasane
P307
●15:30 - 17:00 Hall C Poster Session 1 Tecfidera Gastrointestinal tolerability of delayed-release
dimethyl fumarate in a multicenter, open-label
study of patients with relapsing multiple sclerosis
EJ Fox, A Vasquez, W Grainger, TS Ma, C von
Hehn, J Walsh, J Li, J Zambrano
P309
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 30
Exhibit 29: Thursday – September 11, 2014 Thursday - September 11, 2014
Key? Time Room Type Drug Title Authors ID
15:30 - 17:00 Hall C Poster Session 1 MIF Inhibitor A novel MIF inhibitor as therapy for multiple
sclerosis and stroke
AA Vandenbark, R Meza-Romero, G Benedek, H
Offner,
P310
●15:30 - 17:00 Hall C Poster Session 1 General The changing face of MS: does ARR vary by
epoch?
BC Healy, T Chitnis, F Dangond, HL Weiner P342
15:30 - 17:00 Hall C Poster Session 1 HPP971 The novel Bach1 inhibitor HPP971 uniquely
activates Nrf2 and reduces disease severity in a
mouse model of experimental autoimmune
encephalomyelitis
S-K Kim, J Kassis, O Attucks, J Freeman, Z
Zhong, S Gupta, S Victory, D Polisetti, A Mjalli, R
Andrews, M Kostura, M Guzel, B Gaddam, S
Weaver, K Sakmann, ST Davis
P396
15:30 - 17:00 Hall C Poster Session 1 Gilenya Sustained low rate of brain volume loss under
long-term fingolimod treatment in relapsing
multiple sclerosis: results from the LONGTERMS
study
EW Radue, F Barkhof, J Cohen, R Gottschalk, Y
Zhang, L Cappiello, P von Rosenstiel, L Kappos
P439
15:30 - 17:00 Hall C Poster Session 1 Rebif Evolution of gadolinium-enhancing lesions into
chronic black holes in patients treated with
subcutaneous interferon β-1a in PRISMS and
SPECTRIMS
A Traboulsee, D Li, Y Zhao, R Tam, G Zhao, Y
Cheng, A Riddehough, F Dangond, J Fang, L
Kappos, on behalf of the PRISMS and
SPECTRIMS Working Groups
P470
15:30 - 17:00 Hall C Poster Session 1 Rebif Natural evolution of gadolinium-enhancing lesions
into chronic black holes in multiple sclerosis:
analysis of PRISMS and SPECTRIMS placebo
arms
A Traboulsee, D Li, Y Zhao, R Tam, G Zhao, Y
Cheng, A Riddehough, F Dangond, J Fang, L
Kappos, on behalf of the PRISMS and
SPECTRIMS Working Groups
P473
17:00 - 17:45 Auditorium Hot Topic 2: New routes of drug
development
General Repurposing drugs for disease modification in
multiple sclerosis
K Schmierer HT2.1
17:00 - 17:45 Auditorium Hot Topic 2: New routes of drug
development
General A perspective on generic medications to treat MS JA Cohen HT2.2
17:00 - 17:45 Auditorium Hot Topic 2: New routes of drug
development
General From genetic findings to drug discovery: taking
the first step
NA Patsopoulos, JM Replogle, HT2.3
17:00 - 17:45 Small Ballroom
(302-304-306)
Hot Topic 3: Symptomatic and
rehabilitation strategies
General Cognitive impairment MP Amato HT3.1
●18:00 - 19:00 Auditorium Satellite Symposium Satellite
Symposium
Evolving Insights Into MS Pathology: Can We
Ever Stop Disease Worsening?
Teva - - - - -
●19:15 - 20:15 Small Ballroom Satellite Symposium Satellite
Symposium
Innovation and Optimization: Engaging Today's
Patients
Merck KGaA - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 31
Exhibit 30: Friday – September 12, 2014 Friday - September 12, 2014
Key? Time Room Type Drug Title Authors ID
●
08:15 - 09:15 Auditorium Free Communication 1 Daclizumab Primary results of DECIDE: a randomized, double-
blind, double-dummy, active-controlled trial of
daclizumab HYP vs. Interferon β-1a in RRMS
patients
L Kappos, K Selmaj, DL Arnold, E Havrdova, A
Boyko, M Kaufman, H Wiendl, J Rose, S
Greenberg0, E Demirhan, M Sweetser, K Riester,
J Elkins
FC1.1
●
08:15 - 09:15 Auditorium Free Communication 1 Generic Copaxone Generic glatiramer acetate is equivalent to
copaxone on efficacy and safety: results of the
randomized double-blind GATE trial in multiple
sclerosis
JA Cohen, A Belova, K Selmaj, C Wolf, JJL
Oberyé, ERW van den Tweel, NP Koper, G
Voortman, F Barkhof, on behalf of the GATE
Study Group
FC1.2
08:15 - 09:15 Auditorium Free Communication 1 Laquinimod Long-term follow-up of laquinimod in patients with
relapsing-remitting multiple sclerosis
G Comi, TL Vollmer, N Ashtamker, Y Sidi, D
Ladkani, T Gorfine, PS Sørensen
FC1.3
●08:15 - 09:15 Auditorium Free Communication 1 Alemtuzumab Disease-free outcomes with alemtuzumab: 3-year
follow-up of the CARE-MS studies
E Havrdova, DL Arnold, J Palmer, DH Margolin,
on behalf of CARE-MS I and CARE-MS II Study
Investigators
FC1.4
08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 Gilenya Inclusion of brain volume loss in a revised
measure of multiple sclerosis disease-activity
freedom: the effect of fingolimod
L Kappos, E-W Radue, MS Freedman, B Cree,
MP Sormani, N Sfikas, G Francis, D Tomic, D
Piani Meier, N De Stefano
FC1.5
●08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 Alemtuzumab Alemtuzumab improves MRI outcomes in
treatment-naive active relapsing-remitting multiple
sclerosis patients: three-year follow-up from
CARE-MS I
DL Arnold, F Barkhof, JA Cohen, EJ Fox, KW
Selmaj, DH Margolin, J Palmer, E Fisher, on
behalf of CARE-MS I Investigators
FC2.2
●08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 Gilenya Brain volume change by quartile and disability
progression in multiple sclerosis: a 4-year analysis
of the phase 3 FREEDOMS trial and its extension
D Jeffery, E Verdun, D Piani Meier, S Ritter, P
Chin, E-W Radue, W Camu
FC2.3
●08:15 - 09:15 Small Ballroom
(302-304-306)
Free Communication 2 MOR103 Safety and pharmacokinetics of MOR103, a
human antibody to granulocyte-macrophage
colony-stimulating factor, in patients with multiple
sclerosis
CS Constantinescu, A Asher, W Fryze, W
Kozubski, F Wagner, JJ Aram, R Tanasescu, RP
Korolkiewicz, S Steidl, T Sprenger, WE Radue
FC2.4
●08:15 - 09:15 Grand Ballroom Free Communication 3 Plegridy Clinical efficacy of peginterferon beta-1a in
relapsing-remitting multiple sclerosis: 2-year data
from the phase 3 ADVANCE study
PA Calabresi, BC Kieseier, DL Arnold, L Balcer, A
Boyko, J Pelletier, S Liu, Y Zhu, SI Sheikh, A
Seddighzadeh, A Deykin, S Hung
FC2.5
●08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone TIW GLACIER: open-label, randomized
safety/tolerability study of glatiramer acetate
40mg/mL three times weekly versus 20mg/mL
daily in RRMS
JS Wolinsky, DW Dietrich, TE Borresen, BF
Gilder, JR Steinerman, Y Sidi, A Vainstein, S
Kolodny, V Knappertz, GLACIER Study Group
FC3.2
08:15 - 09:15 Grand Ballroom Free Communication 3 Copaxone + Estriol A combination trial of estriol plus glatiramer
acetate in relapsing-remitting multiple sclerosis:
effect on disabilities
R Voskuhl, H Wang, G Lee, B Giesser, CH Tse, R
Elashoff, Estriol Relapse Trial Study Group
FC3.3
08:15 - 09:15 Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers Tecfidera Long-term follow-up of the effect of delayed-
release dimethyl fumarate on no evident disease
activity in patients with multiple sclerosis
G Giovannoni, R Gold, RJ Fox, L Kappos, T
Phillips, A Zhang, NC Kurukulasuriya, E Havrdova
FC3.5
●09:45 - 11:15 Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers General Biomarkers of treatment response to MS disease
therapies
S Dhib-Jalbut PS7.2
09:45 - 11:15 Small Ballroom
(302-304-306)
Parallel Session 7: Biomarkers General Immunological biomarkers that identify MS
patients with high probability of being free of
disease activity if treated with IFN-beta
JC Alvarez-Cermeño, R Alenda, L Costa-
Frossard, R Alvarez-Lafuente, C Picon, M Espiño,
E Roldan, R Arroyo, E Rodriguez-Martin, LM Villar
PS7.3
09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing
neuroprotection
General Pathways to neurodegeneration: insights from
imaging in MS and other neurodegenerative
disorders
M Inglese PS8.1
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 32
Exhibit 31: Friday – September 12, 2014 Friday - September 12, 2014
Key? Time Room Type Drug Title Authors ID
●09:45 - 11:15 Grand Ballroom Parallel Session 8: Assessing
neuroprotection
General Update on completed and ongoing
neuroprotection and repair trials
J Chataway PS8.2
09:45 - 11:15 Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Differentiation and quantification of inflammation,
demyelination, and axon injury in human multiple
sclerosis using diffusion basis spectrum imaging
Y Wang, P Sun, Q Wang, C-W Chiang, RE
Schmidt, RT Naismith, AH Cross, S-K Song
PS8.6
09:45 - 11:15 Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Is no evidence of disease activity a realistic
treatment target?
H-P Hartung PS9.1
09:45 - 11:15 Auditorium Parallel Session 9: Treatment
strategies in clinical practice
General Treatment algorithms in patients with ongoing
disease activity
X Montalban PS9.2
09:45 - 11:15 Small Ballroom
(302-304-306)
Parallel Session 10: Immune
mechanisms
Copaxone +
Interferon Beta-1a
Early on-treatment T2 and T1 subtraction MRI
predicts imaging and clinical outcomes in the
CombiRx cohort
F Lalys, L Freeman, TD Staewen, JA Lincoln, F
Nelson, S Datta, PA Narayana, SS Cofield, T
Gustafson, GR Cutter, FD Lublin, JS Wolinsky,
CombiRx Investigators
PS9.6
●12:00 - 13:00 Auditorium Satellite Symposium Satellite
Symposium
Evolving Strategies to Improve Patient-Clinician
Communication and Treatment Adherence in
Multiple Sclerosis
Teva - - - - -
13:15 - 14:45 Grand Ballroom Parallel Session 11: Gray matter
pathology and mechanisms of
progression
General Demyelinating lesions in multiple sclerosis:
experimental evidence indicating why, how and
where they may form
RA Desai, AL Davies, M Kasti, F Laulund, KJ
Smith
PS10.3
13:15 - 14:45 Auditorium Parallel Session 12: Study design
and endpoints
General Is primary progressive MS a distinct disease? S Vukusic PS11.2
13:15 - 14:45 Auditorium Parallel Session 12: Study design
and endpoints
General Pragmatic clinical trials and observational studies M Trojano PS12.2
13:15 - 14:45 Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Defining brain volume cut-offs to predict disability
progression in MS: an analysis of a large cohort of
relapsing-remitting MS patients
MP Sormani, L Kappos, EW Radue, J Cohen, F
Barkhof, T Sprenger, D Piani Meier, D Häring, D
Tomic, N De Stefano
PS12.3
14:45 - 16:15 Hall C Poster Session 2 Gilenya Identification of tissue-specific MRI markers to
assess protection and repair in response to
fingolimod
C Berrios-Otero, L Fleysher, J Zhang, E
Fieremans, G John, M Inglese
P497
14:45 - 16:15 Hall C Poster Session 2 M356 Comparative efficacy between a generic (M356)
and brand Copaxone® (glatiramer acetate
injection) in an animal model of multiple sclerosis
C Honan, TC Ganguly, I Fier, GV Kaundinya P600
14:45 - 16:15 Hall C Poster Session 2 General Histamine H3 receptor negatively regulates
oligodendrocyte differentiation and myelination
RR Wang, Y Chen, T Guo, W Zhen, TB Guo, RY
Zhao, AA Liu, JP Rubio, D Krull, J Lu, M Song, P
Thompson, S Wang, JC Richardson
P621
14:45 - 16:15 Hall C Poster Session 2 General Optic neuritis associated with multiple sclerosis:
VEPs sensitive in acute phase, OCT useful in
chronic phase
G Di Maggio, RI Santangelo, S Guerrieri, L
Ferrari, S Medaglini, M Rodegher, B Colombo, L
Moiola, U Del Carro, V Martinelli, G Comi, L
Leocani
P676
14:45 - 16:15 Hall C Poster Session 2 General Visual evoked potentials and optic coherence
tomography in monitoring involvement of visual
pathways in multiple sclerosis
L Leocani, S Guerrieri, G Di Maggio, R
Santangelo, L Ferrari, S Medaglini, M Rodegher,
B Colombo, L Moiola, U Del Carro, V Martinelli, G
Comi
P704
14:45 - 16:15 Hall C Poster Session 2 NDC-1308 NDC-1308, a gain of function estradiol analog for
inducing remyelination in multiple sclerosis
patients
SH Nye, S Medicetty, BD Trapp, JG Yarger P710
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 33
Exhibit 32: Friday – September 12, 2014 Friday - September 12, 2014
Key? Time Room Type Drug Title Authors ID
14:45 - 16:15 Hall C Poster Session 2 Anti-SEMA4D mAb Anti- SEMA4D antibody ameliorates pathogenic
processes related to multiple sclerosis
AS Jonason, E Klimatcheva, T Fisher, C Reilly, L
Winter, J Veeraraghavan, M Doherty, C Mallow, J
Seils, H Bussler, S Torno, R Kirk, A Howell, M
Scrivens, L Balch, T Pandina, W Wang, E Evans,
WJ Bowers, M Paris, J Leonard, V Iddison, E
Smith, M Zauderer
P712
14:45 - 16:15 Hall C Poster Session 2 KB3944 KB3944, a selective estrogen receptor beta
agonist, in preclinical development for
neuroprotective and regenerative therapy of
multiple sclerosis
P Fagergren, S Tiwari-Woodruff, M Osterlund P715
14:45 - 16:15 Hall C Poster Session 2 General Small molecule inducers of oligodendrocyte
differentiation
B Bai, R Avila, M Torres-Castillo, S Lunn, S
Medicetty, B Trapp
P721
●14:45 - 16:15 Hall C Poster Session 2 GSK239512 The effects of GSK239512 on lesion
remyelination in a relapsing remitting MS
population: design of a phase 2a imaging study
C Schwartzbach, R Grove, P Thompson, O Graff,
MA Peykamian, K Harding, J Hilpert, R Brown, D
Arnold
P726
14:45 - 16:15 Hall C Poster Session 2 General A high throughput flow cytometry based approach
to assess the differentiation of oligodendrocyte
precursor cells into mature oligodendrocytes
C Hollins, H Sandig, C Glover, C Jones, M
Sleeman
P728
●14:45 - 16:15 Hall C Poster Session 2 BIIB033 A phase II study of the anti-LINGO-1 monoclonal
antibody, BIIB033, in subjects with acute optic
neuritis: baseline data
D Cadavid, F Ziemssen, H Butzkueven, LJ Balcer,
SL Galetta, A Rahilly, T Dong-Si, L Xu, T
Ziemssen, RENEW Study Group
P731
14:45 - 16:15 Hall C Poster Session 2 General Clinical and molecular markers that predict
severity of relapsing-remitting MS (RRMS)
disease outcomes
J Goyal, J Bienkowska, R Hosur, M Yang, S
Feng, V Viglietta, D Mikol
P761
14:45 - 16:15 Hall C Poster Session 2 Rebif Assessing a predictive score for long-term
disability progression in relapsing-remitting
multiple sclerosis: 7/8-year follow-up in the
PRISMS study
M Freedman, A-F Ben-Amor, E Aycardi, D Issard,
F Casset-Semanaz, M-P Sormani
P765
14:45 - 16:15 Hall C Poster Session 2 Rebif Assessing a predictive score for disease activity in
secondary progressive multiple sclerosis: post-
hoc analysis of data from the SPECTRIMS study
M Freedman, A-F Ben-Amor, E Aycardi, D Issard,
F Casset-Semanaz, M-P Sormani
P766
●14:45 - 16:15 Hall C Poster Session 2 Tysabri Correlations between patient-reported ambulatory
function (MSWS-12) and objective disability
measurements in SPMS: analysis of ASCEND
baseline data
D Mikol, MS Freedman, MD Goldman, H-P
Hartung, E Havrdova, D Jeffery, R Kapoor, A
Miller, F Sellebjerg, D Cadavid, Y Chen
P777
14:45 - 16:15 Hall C Poster Session 2 General Identifying an important change threshold for the
Multiple Sclerosis Walking Scale-12 (MSWS-12)
L Mehta, M McNeill, J Hobart, K Wyrwich, JL
Poon, P Auguste, ZJ Zhong, J Elkins
P783
14:45 - 16:15 Hall C Poster Session 2 General Psychometric testing of the early mobility
impairment questionnaire for multiple sclerosis
T Ziemssen, A Mathias, C Coon, S Agarwal, R
Shah, G Phillips
P784
14:45 - 16:15 Hall C Poster Session 2 Ampyra Evaluation of patient health status in the PR-
fampridine ENABLE study using SF-36-derived
utility scores
A Lee, P Wang, M Yeh P785
14:45 - 16:15 Hall C Poster Session 2 Tecfidera An interim analysis of quality of life in patients with
relapsing-remitting multiple sclerosis treated with
delayed-release dimethyl fumarate
M Kita, RJ Fox, R Gold, G Giovannoni, T Phillips,
SP Sarda, M Okwuokenye, J Kong, R Zhang, NC
Kurukulasuriya, L Kappos
P790
●14:45 - 16:15 Hall C Poster Session 2 Plegridy Impact of treatment-related flu-like symptoms and
injection site reactions on quality of life in patients
with multiple sclerosis: ADVANCE study
ET Kinter, S Guo, A Altincatal, I Proskorovsky, G
Phillips, B Sperling, G Sabatella
P799
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 34
Exhibit 33: Friday – September 12, 2014 Friday - September 12, 2014
Key? Time Room Type Title Authors ID
14:45 - 16:15 Hall C Poster Session 2 Alemtuzumab Defining clinical meaning of patient-reported
outcomes with disability assessment in multiple
sclerosis: an analysis of the CARE-MS II study
L Steinman, H Wang, Y Liu, J Palmer, Q Zhang,
on behalf of the CARE-MS II Investigators
P802
14:45 - 16:15 Hall C Poster Session 2 Tecfidera Delayed-release dimethyl fumarate and
pregnancy: preclinical studies and pregnancy
outcomes from clinical trials and postmarketing
experience
R Gold, JT Phillips, E Havrdova, A Bar-Or, L
Kappos, H Yuan, P Valencia, L Oliva, M Novas, J
Li, MT Sweetser, NC Kurukulasuriya, V Viglietta,
RJ Fox
P839
14:45 - 16:15 Hall C Poster Session 2 Alemtuzumab Pregnancy outcomes in the alemtuzumab MS
clinical development program
P McCombe, A Achiron, DH Margolin, J Palmer, P
Oyuela, on behalf of the CAMMS, CARE-MS I,
and CARE-MS II Investigators
P842
14:45 - 16:15 Hall C Poster Session 2 MSCs Cytogenetic analysis of culture-expanded human
mesenchymal stem cells used in a phase I clinical
trial in multiple sclerosis
SM Planchon, I Warshawsky, JS Reese, KM
Drake, JA Cohen
P890
14:45 - 16:15 Hall C Poster Session 2 MSCs Immune function monitoring in a phase I trial of
autologous culture-expanded mesenchymal stem
cell transplantation for relapsing multiple sclerosis
A Bar-Or, M-N Boivin, A Rozenberg, T Johnson, C
Belabani, G Morisse, J Sirois, S Lai Wing Sun, S
Vanamala, A Del Rosario Villalobos, J Reese Koc,
S Morrison, RA Bermel, PB Imrey, SM Planchon,
JA Cohen
P892
14:45 - 16:15 Hall C Poster Session 2 ACTiMuS Assessment of bone marrow-derived cell therapy
in progressive multiple sclerosis (ACTiMuS)
CM Rice, DI Marks, Y Ben-Shlomo, N Evangelou,
C Metcalfe, P Walsh, DA Cottrell, NM Kane, A
Wilkins, NJ Scolding
P902
14:45 - 16:15 Hall C Poster Session 2 Ampyra Walking ability and balance in patients with
multiple sclerosis treated with prolonged-release
fampridine: randomized, double-blind MOBILE
study
R Hupperts, J Lycke, C Short, C Gasperini, M
McNeill, R Medori, L Mehta, J Elkins
P922
14:45 - 16:15 Hall C Poster Session 2 Ampyra Safety, quality of life, and walking ability with PR-
fampridine treatment in clinical practice in France:
interim results of the LIBERATE study
J-P Neau, G Castelnovo, T Soisson, A
Kwiatkowski, M McNeill, M Yeh
P924
●
14:45 - 16:15 Hall C Poster Session 2 XP23829 Steady state pharmacokinetics and blood
lymphocyte responses in healthy subjects dosed
with XP23829, a novel fumaric acid ester for
multiple sclerosis
L Steinman, RJ Fox, D Lissin, L Clark, K Cundy P958
16:15 - 17:00 Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Epigenome-wide studies: what can we learn from
them?
P Casaccia HT4.1
16:15 - 17:00 Small Ballroom
(302-304-306)
Hot Topic 4: Remyelination General Remyelination in the adult central nervous
system: mechanisms and perspectives
C Lubetzki HT4.2
16:15 - 17:00 Grand Ballroom Hot Topic 5: Inflammation and
neurodegeneration
General Fluorosamine that targets scar components is a
novel therapeutic that promotes myelin
regeneration and reduces inflammation in
demyelination models
M Keough, J Rogers, P Zhang, S Jensen, E
Stephenson, J Plemel, M Hurlbert, C-C Ling, VW
Yong
HT4.3
16:15 - 17:00 Auditorium Hot Topic 6: Society and MS General Neuro-axonal damage in MS may be mediated by
interaction of innate immunity and anti-axonal
antibodies
JD Black, MS Freedman HT5.3
16:15 - 17:00 Hall C Poster Session 2 General Patients as partners in clinical research - Does
the Internet harm or help?
P Wicks HT6.2
●17:15 - 18:15 Auditorium Satellite Symposium Satellite
Symposium
Treatment Decisions at the Interactions of Trials
and Practice
Biogen idec - - - - -
●18:30 - 19:30 Small Ballroom Satellite Symposium Satellite
Symposium
Treating to target and beyond: Is improvement in
functioning a realistic treatment goal in multiple
sclerosis?
AbbVie - - - - -
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 35
Exhibit 34: Saturday, September 13, 2014 Saturday - September 13, 2014
Key? Time Room Type Title Authors ID
●07:15 - 08:15 Small Ballroom
(302-304-306)
Industry Support Satellite Symposia Satellite
Symposium
Shifting the Paradigm in Multiple Sclerosis
Treatment by Targeting New Pathways
Roche - - - - -
●08:30 - 10:00 Auditorium Late Breaking News RPC1063 Phase 2 results of the RADIANCE trial: a
randomized, double-blind, placebo-controlled trial
of oral RPC1063 in relapsing multiple sclerosis
J Cohen, DL Arnold, G Comi, A Bar-Or, S
Gujrathi, JP Hartung, A Olson, M Cravets, PA
Frohna, K Selmaj
LB1.1
08:30 - 10:00 Auditorium Late Breaking News General The Genomic map of multiple sclerosis: over 45
novel susceptibility variants and translation of
genetics to biology
P De Jager, International MS Genetics
Consortium
LB1.4
10:30 - 12:00 Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Clinical Research Highlights Speaker: Ellen Mowry PL2.2
10:30 - 12:00 Auditorium Plenary Session 2 General ACTRIMS-ECTRIMS Basic Research Highlights Speaker: Finn Sellebjerg PL2.3
10:00 - 10:30 Outside Hall C Late Breaking News Posters Tecfidera DMF protects neural stem/progenitor cells and
differentiated neurons from oxidative damage
through regulating anti-oxidative stress genes
S Chuikov, S Taitano, Q Wu, Y Mao-Draayer LBP14
10:00 - 10:30 Outside Hall C Late Breaking News Posters GNbAC1 HERV-W envelope protein inhibits
oligodendroglial cell differentiation which can be
abrogated by the neutralizing antibody GNbAC1
D Kremer, M Foerster, T Schichel, P Goettle, H-P
Hartung, H Perron, P Kuery
LBP15
10:00 - 10:30 Outside Hall C Late Breaking News Posters GNbAC1 Follow-up of MS patients from phase IIa clinical
study of GNbAC1 reveals unexpected decrease of
HERV-W endogenous retrovirus genes
expression
R Faucard, A Madeira, N Gehin, T Derfuss, H-P
Hartung, R Du Pasquier, L Kappos, P Lalive, H
Porchet, AB Lang, F Curtin, HJF Perron
LBP16
10:00 - 10:30 Outside Hall C Late Breaking News Posters Betaseron Clinical outcomes in patients with CIS treated with
interferon beta-1b: 11-year follow-up of BENEFIT
L Kappos, G Edan, MS Freedman, X Montalbán,
DH Miller, H-P Hartung, B Hemmer, EJ Fox, F
Barkhof, S Schippling0, A Schulze, D Pleimes, C
Pohl, R Sandbrink, G Suarez, E-M Wicklein, on
behalf of the BENEFIT Study Group
LBP17
10:00 - 10:30 Outside Hall C Late Breaking News Posters Siponomid Impact of siponimod (BAF 312) on CNS
remyelination in a transgenic Xenopus model
A Mannioui, L Azoyan, D Du Pasquier, B Zalc LBP6
10:00 - 10:30 Outside Hall C Late Breaking News Posters General Oligodendroglial cells and signs of remyelination
are present in a subset of early active and inactive
MS lesions despite pronounced axonal damage
E Bahn, C Theodossiou-Wegner, W Brück LBP9
LEGEND
General Novartis
Acorda Receptos
Bayer Sanofi
Biogen Idec Teva
Merck KGaA Xenoport
Multiple Companies Other
GSK Source: Company data, Credit Suisse estimates
03 September 2014
ACTRIMS-ECTRIMS 2014 36
Companies Mentioned (Price as of 02-Sep-2014)
AbbVie Inc. (ABBV.N, $55.07) Acorda Therapeut (ACOR.OQ, $32.17) Biogen Idec (BIIB.OQ, $342.68) GENMAB (GEN.CO, Dkr223.5) GlaxoSmithKline plc (GSK.L, 1454.5p) MorphoSys (MORG.DE, €72.46) Novartis (NOVN.VX, SFr85.8) Receptos (RCPT.OQ, $52.75) Sanofi (SASY.PA, €83.76) Teva Pharmaceutical Ind. (TEVA.N, $52.14) XenoPort (XNPT.OQ, $5.18)
Disclosure Appendix
Important Global Disclosures
Ravi Mehrotra PhD, European Pharma Team, Vamil Divan, MD, Koon Ching PhD and Ari Jahja each certify, with respect to the companies or securities that the individual analyzes, that (1) the views expressed in this report accurately reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.
The analyst(s) responsible for preparing this research report received Compensation that is based upon various factors including Credit Suisse's total revenues, a portion of which are generated by Credit Suisse's investment banking activities
As of December 10, 2012 Analysts’ stock rating are defined as follows:
Outperform (O) : The stock’s total return is expected to outperform the relevant benchmark*over the next 12 months.
Neutral (N) : The stock’s total return is expected to be in line with the relevant benchmark* over the next 12 months.
Underperform (U) : The stock’s total return is expected to underperform the relevant benchmark* over the next 12 months.
*Relevant benchmark by region: As of 10th December 2012, Japanese ratings are based on a stock’s total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attractive investment opportunities. As of 2nd October 2012, U.S. and Canadian as well as European ra tings are based on a stock’s total return relative to the analyst's coverage universe which consists of all companies covered by the analyst within the relevant sector, with Outperforms representing the most attractive, Neutrals the less attractive, and Underperforms the least attracti ve investment opportunities. For Latin American and non-Japan Asia stocks, ratings are based on a stock’s total return relative to the average total return of the relevant country or regional benchmark; prior to 2nd October 2012 U.S. and Canadian ratings were based on (1) a stock’s absolute total return potential to its current share price and (2) the relative attractiveness of a stock’s total return potential within an analyst’s coverage universe. For Australian and New Zealand stocks, 12 -month rolling yield is incorporated in the absolute total return calculation and a 15% and a 7.5% threshold replace the 10-15% level in the Outperform and Underperform stock rating definitions, respectively. The 15% and 7.5% thresholds replace the +10-15% and -10-15% levels in the Neutral stock rating definition, respectively. Prior to 10th December 2012, Japanese ratings were based on a stock’s total return relative to the average total return of the relevant country or regional benchmark.
Restricted (R) : In certain circumstances, Credit Suisse policy and/or applicable law and regulations preclude certain types of communications, including an investment recommendation, during the course of Credit Suisse's engagement in an investment banking transaction and in certain other circumstances.
Volatility Indicator [V] : A stock is defined as volatile if the stock price has moved up or down by 20% or more in a month in at least 8 of the past 24 months or the analyst expects significant volatility going forward.
Analysts’ sector weightings are distinct from analysts’ stock ratings and are based on the analyst’s expectations for the fundamentals and/or valuation of the sector* relative to the group’s historic fundamentals and/or valuation:
Overweight : The analyst’s expectation for the sector’s fundamentals and/or valuation is favorable over the next 12 months.
Market Weight : The analyst’s expectation for the sector’s fundamentals and/or valuation is neutral over the next 12 months.
Underweight : The analyst’s expectation for the sector’s fundamentals and/or valuation is cautious over the next 12 months.
*An analyst’s coverage sector consists of all companies covered by the analyst within the relevant sector. An analyst may cov er multiple sectors.
03 September 2014
ACTRIMS-ECTRIMS 2014 37
Credit Suisse's distribution of stock ratings (and banking clients) is:
Global Ratings Distribution
Rating Versus universe (%) Of which banking clients (%)
Outperform/Buy* 44% (53% banking clients)
Neutral/Hold* 40% (51% banking clients)
Underperform/Sell* 13% (44% banking clients)
Restricted 3%
*For purposes of the NYSE and NASD ratings distribution disclosure requirements, our stock ratings of Outperform, Neutral, an d Underperform most closely correspond to Buy, Hold, and Sell, respectively; however, the meanings are not the same, as our stock ratings are determined on a relative basis. (Please refer to definitions above.) An investor's decision to buy or sell a security should be based on investment objectives, current holdin gs, and other individual factors.
Credit Suisse’s policy is to update research reports as it deems appropriate, based on developments with the subject company, the sector or the market that may have a material impact on the research views or opinions stated herein.
Credit Suisse's policy is only to publish investment research that is impartial, independent, clear, fair and not misleading. For more detail please refer to Credit Suisse's Policies for Managing Conflicts of Interest in connection with Investment Research: http://www.csfb.com/research and analytics/disclaimer/managing_conflicts_disclaimer.html
Credit Suisse does not provide any tax advice. Any statement herein regarding any US federal tax is not intended or written to be used, and cannot be used, by any taxpayer for the purposes of avoiding any penalties.
Important Regional Disclosures
Singapore recipients should contact Credit Suisse AG, Singapore Branch for any matters arising from this research report.
Restrictions on certain Canadian securities are indicated by the following abbreviations: NVS--Non-Voting shares; RVS--Restricted Voting Shares; SVS--Subordinate Voting Shares.
Individuals receiving this report from a Canadian investment dealer that is not affiliated with Credit Suisse should be advised that this report may not contain regulatory disclosures the non-affiliated Canadian investment dealer would be required to make if this were its own report.
For Credit Suisse Securities (Canada), Inc.'s policies and procedures regarding the dissemination of equity research, please visit http://www.csfb.com/legal_terms/canada_research_policy.shtml.
As of the date of this report, Credit Suisse acts as a market maker or liquidity provider in the equities securities that are the subject of this report.
Principal is not guaranteed in the case of equities because equity prices are variable.
Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.
To the extent this is a report authored in whole or in part by a non-U.S. analyst and is made available in the U.S., the following are important disclosures regarding any non-U.S. analyst contributors: The non-U.S. research analysts listed below (if any) are not registered/qualified as research analysts with FINRA. The non-U.S. research analysts listed below may not be associated persons of CSSU and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.
Credit Suisse Securities (Europe) Limited ......................................................................................................................... European Pharma Team
For Credit Suisse disclosure information on other companies mentioned in this report, please visit the website at https://rave.credit-suisse.com/disclosures or call +1 (877) 291-2683.
03 September 2014
ACTRIMS-ECTRIMS 2014 38
References in this report to Credit Suisse include all of the subsidiaries and affiliates of Credit Suisse operating under its investment banking division. For more information on our structure, please use the following link: https://www.credit-suisse.com/who_we_are/en/This report may contain material that is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse AG or its affiliates ("CS") to any registration or licensing requirement within such jurisdiction. All material presented in this report, unless specifically indicated otherwise, is under copyright to CS. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of CS. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of CS or its affiliates. The information, tools and material presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. CS may not have taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. CS will not treat recipients of this report as its customers by virtue of their receiving this report. The investments and services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about such investments or investment services. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you. CS does not advise on the tax consequences of investments and you are advised to contact an independent tax adviser. Please note in particular that the bases and levels of taxation may change. Information and opinions presented in this report have been obtained or derived from sources believed by CS to be reliable, but CS makes no representation as to their accuracy or completeness. CS accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to CS. This report is not to be relied upon in substitution for the exercise of independent judgment. CS may have issued, and may in the future issue, other communications that are inconsistent with, and reach different conclusions from, the information presented in this report. Those communications reflect the different assumptions, views and analytical methods of the analysts who prepared them and CS is under no obligation to ensure that such other communications are brought to the attention of any recipient of this report. Some investments referred to in this report will be offered solely by a single entity and in the case of some investments solely by CS, or an associate of CS or CS may be the only market maker in such investments. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by CS and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments. Investors in securities such as ADR's, the values of which are influenced by currency volatility, effectively assume this risk. Structured securities are complex instruments, typically involve a high degree of risk and are intended for sale only to sophisticated investors who are capable of understanding and assuming the risks involved. The market value of any structured security may be affected by changes in economic, financial and political factors (including, but not limited to, spot and forward interest and exchange rates), time to maturity, market conditions and volatility, and the credit quality of any issuer or reference issuer. Any investor interested in purchasing a structured product should conduct their own investigation and analysis of the product and consult with their own professional advisers as to the risks involved in making such a purchase. Some investments discussed in this report may have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when that investment is realised. Those losses may equal your original investment. Indeed, in the case of some investments the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support those losses. Income yields from investments may fluctuate and, in consequence, initial capital paid to make the investment may be used as part of that income yield. Some investments may not be readily realisable and it may be difficult to sell or realise those investments, similarly it may prove difficult for you to obtain reliable information about the value, or risks, to which such an investment is exposed. This report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of CS, CS has not reviewed any such site and takes no responsibility for the content contained therein. Such address or hyperlink (including addresses or hyperlinks to CS's own website material) is provided solely for your convenience and information and the content of any such website does not in any way form part of this document. Accessing such website or following such link through this report or CS's website shall be at your own risk. This report is issued and distributed in Europe (except Switzerland) by Credit Suisse Securities (Europe) Limited, One Cabot Square, London E14 4QJ, England, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. This report is being distributed in Germany by Credit Suisse Securities (Europe) Limited Niederlassung Frankfurt am Main regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht ("BaFin"). This report is being distributed in the United States and Canada by Credit Suisse Securities (USA) LLC; in Switzerland by Credit Suisse AG; in Brazil by Banco de Investimentos Credit Suisse (Brasil) S.A or its affiliates; in Mexico by Banco Credit Suisse (México), S.A. (transactions related to the securities mentioned in this report will only be effected in compliance with applicable regulation); in Japan by Credit Suisse Securities (Japan) Limited, Financial Instruments Firm, Director-General of Kanto Local Finance Bureau (Kinsho) No. 66, a member of Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association; elsewhere in Asia/ Pacific by whichever of the following is the appropriately authorised entity in the relevant jurisdiction: Credit Suisse (Hong Kong) Limited, Credit Suisse Equities (Australia) Limited, Credit Suisse Securities (Thailand) Limited, regulated by the Office of the Securities and Exchange Commission, Thailand, having registered address at 990 Abdulrahim Place, 27th Floor, Unit 2701, Rama IV Road, Silom, Bangrak, Bangkok 10500, Thailand, Tel. +66 2614 6000, Credit Suisse Securities (Malaysia) Sdn Bhd, Credit Suisse AG, Singapore Branch, Credit Suisse Securities (India) Private Limited (CIN no. U67120MH1996PTC104392) regulated by the Securities and Exchange Board of India (registration Nos. INB230970637; INF230970637; INB010970631; INF010970631), having registered address at 9th Floor, Ceejay House, Dr.A.B. Road, Worli, Mumbai - 18, India, T- +91-22 6777 3777, Credit Suisse Securities (Europe) Limited, Seoul Branch, Credit Suisse AG, Taipei Securities Branch, PT Credit Suisse Securities Indonesia, Credit Suisse Securities (Philippines ) Inc., and elsewhere in the world by the relevant authorised affiliate of the above. Research on Taiwanese securities produced by Credit Suisse AG, Taipei Securities Branch has been prepared by a registered Senior Business Person. Research provided to residents of Malaysia is authorised by the Head of Research for Credit Suisse Securities (Malaysia) Sdn Bhd, to whom they should direct any queries on +603 2723 2020. This report has been prepared and issued for distribution in Singapore to institutional investors, accredited investors and expert investors (each as defined under the Financial Advisers Regulations) only, and is also distributed by Credit Suisse AG, Singapore branch to overseas investors (as defined under the Financial Advisers Regulations). By virtue of your status as an institutional investor, accredited investor, expert investor or overseas investor, Credit Suisse AG, Singapore branch is exempted from complying with certain compliance requirements under the Financial Advisers Act, Chapter 110 of Singapore (the "FAA"), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder, in respect of any financial advisory service which Credit Suisse AG, Singapore branch may provide to you. This research may not conform to Canadian disclosure requirements. In jurisdictions where CS is not already registered or licensed to trade in securities, transactions will only be effected in accordance with applicable securities legislation, which will vary from jurisdiction to jurisdiction and may require that the trade be made in accordance with applicable exemptions from registration or licensing requirements. Non-U.S. customers wishing to effect a transaction should contact a CS entity in their local jurisdiction unless governing law permits otherwise. U.S. customers wishing to effect a transaction should do so only by contacting a representative at Credit Suisse Securities (USA) LLC in the U.S. Please note that this research was originally prepared and issued by CS for distribution to their market professional and institutional investor customers. Recipients who are not market professional or institutional investor customers of CS should seek the advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. This research may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority or in respect of which the protections of the Prudential Regulation Authority and Financial Conduct Authority for private customers and/or the UK compensation scheme may not be available, and further details as to where this may be the case are available upon request in respect of this report. CS may provide various services to US municipal entities or obligated persons ("municipalities"), including suggesting individual transactions or trades and entering into such transactions. Any services CS provides to municipalities are not viewed as "advice" within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act. CS is providing any such services and related information solely on an arm's length basis and not as an advisor or fiduciary to the municipality. In connection with the provision of the any such services, there is no agreement, direct or indirect, between any municipality (including the officials, management, employees or agents thereof) and CS for CS to provide advice to the municipality. Municipalities should consult with their financial, accounting and legal advisors regarding any such services provided by CS. In addition, CS is not acting for direct or indirect compensation to solicit the municipality on behalf of an unaffiliated broker, dealer, municipal securities dealer, municipal advisor, or investment adviser for the purpose of obtaining or retaining an engagement by the municipality for or in connection with Municipal Financial Products, the issuance of municipal securities, or of an investment adviser to provide investment advisory services to or on behalf of the municipality. If this report is being distributed by a financial institution other than Credit Suisse AG, or its affiliates, that financial institution is solely responsible for distribution. Clients of that institution should contact that institution to effect a transaction in the securities mentioned in this report or require further information. This report does not constitute investment advice by Credit Suisse to the clients of the distributing financial institution, and neither Credit Suisse AG, its affiliates, and their respective officers, directors and employees accept any liability whatsoever for any direct or consequential loss arising from their use of this report or its content. Principal is not guaranteed. Commission is the commission rate or the amount agreed with a customer when setting up an account or at any time after that.
Copyright © 2014 CREDIT SUISSE AG and/or its affiliates. All rights reserved.
Investment principal on bonds can be eroded depending on sale price or market price. In addition, there are bonds on which investment principal can be eroded due to changes in redemption amounts. Care is required when investing in such instruments. When you purchase non-listed Japanese fixed income securities (Japanese government bonds, Japanese municipal bonds, Japanese government guaranteed bonds, Japanese corporate bonds) from CS as a seller, you will be requested to pay the purchase price only.
ACTRIMS-ECTRIMS Planner.doc